

## CURRICULUM VITAE

### **Bronwen Elizabeth Shaw, MBChB, PhD**

*Chief Scientific Director, Center for International Blood and Marrow Transplant Research  
(CIBMTR)*

*Professor of Medicine, Medical College of Wisconsin*

**OFFICE ADDRESS:** Froedtert & the Medical College of Wisconsin  
Clinical Cancer Center  
9200 West Wisconsin Avenue, Suite C5500  
Milwaukee, WI 53226

**NATIONALITY:** British, US green card holder

### **EDUCATION:**

1988–1993 MBChB University of Cape Town, South Africa  
July 2000–July 2004 PhD from the University of London, London, UK, “Understanding the immunogenetic and clinical factors which influence the outcome of haematopoietic stem cell transplantation using unrelated donors”.

### **POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:**

1994 **House Officer**, Groote Schuur University Hospital, Cape Town, South Africa  
Apr 1995–Nov 1997 **Medical SHO Rotation**, London, UK  
Dec 1997–June 2000 **Haematology Specialist Registrar (Fellow)**, London, UK  
Aug 2004–Aug 2006 **Fellow in haematology with a specialist interest in Blood and Bone Marrow Transplantation**, Nottingham City University Hospital, Nottingham, UK

### **FACULTY APPOINTMENTS:**

Oct/Nov 2006 **Locum Consultant in Lymphoma and General Haematology**  
St Mary’s Hospital, London, UK  
Dec/Jan 2006/07 **Locum Consultant in Lymphoma and General Haematology**  
Nottingham City University Hospital, Nottingham, UK  
April 2007–July 2014 **Clinical Senior Lecturer and Honorary Consultant in Blood and Marrow Transplantation**  
Institute of Cancer Research/ Royal Marsden NHS Foundation Trust, Sutton, UK  
April 2007–July 2014 **Chief Medical Officer and Clinical Senior Scientist**  
Anthony Nolan, London, UK  
Sept 2014–current **Professor of Medicine, Division of Hematology/Oncology**  
Froedtert & the Medical College of Wisconsin  
Sept 2014–Jan 2019 **Senior Scientific Director**  
Center for International Blood and Marrow Transplant Research (CIBMTR)

Feb 2019–Jan 2020      **Associate Chief Scientific Director**  
Center for International Blood and Marrow Transplant Research  
(CIBMTR)

Feb 2021-current      **Chief Scientific Director CIBMTR MCW**  
Center for International Blood and Marrow Transplant Research  
(CIBMTR)

**SPECIALTY BOARDS AND CERTIFICATION:**

**Board Certified**

American Board of Internal Medicine (ABIM)      9/2019

US USMLE (ECFMG)      12/2014

Membership of the Royal College of Pathologist (London) Part II      9/2005

Diplomate of the Royal College of Pathologist (London) Part I      6/2000

Membership of the Royal College of Physicians (London) Part II      7/1997

Membership of the Royal College of Physicians (London) Part I      7/1996

**Licensure**

Wisconsin State Medical License

**Number**

64139-20

**Issue Date**

9/16/2021

**Expiration**

10/31/2023

**AWARDS AND HONORS:**

2006      British Society for Blood and Marrow Transplantation (BSBMT)  
Scientific day - Best abstract

2007      European Society for Blood and Marrow Transplantation (EBMT)  
Von Bekkum award - Best abstract

**MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:**

- American Society of Haematology (ASH)
- American Society for Cellular Therapy and Transplantation (ASTCT)
- World Marrow Donor Association (WMDA)
- PROMIS Health Organisation (PHO)

**EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:**

**Editorial Board**

- Member of the *Bone Marrow Transplantation Journal* Editorial Review Board, March 2008–March 2014
- Member of the *Frontiers in Alloimmunity and Transplantation* Editorial Review Board, 2011–Present
- Member of the *HLA* Editorial Board, 2016–Present
- Member of the *Advances in Cell and Gene Therapy* Editorial Board, 2017–Present
- Member of the *Transplantation and Cellular Therapy* Editorial Board, 2018–Present

### **Ad-hoc Review**

- Regular reviewer of meeting abstracts and moderator for oral sessions (EBMT, ASH, EHA, BSBMT, Tandem meeting, ISOQOL)
- Regular chair for meeting sessions (EBMT, Tandem meeting, EHA, IHWG, TCT)
- Program committee member for the International Donor Registry Committee (2009–2014, 2020)
- Regular reviewer of Journal articles (e.g. *Blood, Blood Advances, Haematologica, JCO, Cancer, Lancet Oncology, BMT, Transplantation and Cellular Therapy*)

### **LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:**

- Member of the MCW *Council for Women's Advocacy*, 2016–2019
- Associate Program Director for *Hematology-Oncology Fellowship*, 2018–2021
- Co-Chair of the MCW *Investigator Initiated Trial Steering Committee*, 2018–2021
- Member of the MCW *Cancer Center's American Cancer Society Institutional Research Grant (ACS-IRG) Review Committee*, 2019–Present
- Member of the MCW *School of Medicine Rank Committee*, 2020–2023

### **NATIONAL/INTERNATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:**

- Chair of the *Clinical Working Group* and Board Member of the WMDA, July 2008–July 2014
- Member of the *Anthony Nolan Medical Advisory Group*, 2009–2014
- Member of the *UK Cord Blood Working Group*, 2009–2014
- Member of the *Donor Standing Committee* for the WBMT, 2010–Present
- Faculty of *ESH-EBMT Training Course on Haemopoietic Stem Cell Transplantation*, 2011–2014
- Member of the *BSBMT Executive Board*, 2011–2014
- Member of the *Medical Advisory Group* of the UK Strategic Stem Cell Forum, 2011–2014
- Member of the WHO NOTIFY *Group for Vigilance and Surveillance*, 2011–2021, and Editorial lead for the *Living donor group*, 2011–2019
- Member of the *Advisory Committee* for the 5<sup>th</sup>, 6<sup>th</sup> and 7<sup>th</sup> editions of the *Fact/JACIE Clinical Standards*, 2011–2021
- Chair of the *Clinical Trials Committee* of the BSBMT, 2012-2014
- Chair of the *BSBMT Education Group*, 2012-2014
- Member of the *BSBMT Clinical Excellence Award Selection Review Committee*, 2012–2014
- Member of the *Research Oversight Committee* for Genome Quebec: Personalised Cancer Immunotherapy (PI: Perreault), 2013–Present
- Scientific Director of the CIBMTR *Donor Health and Safety Committee*, 2014–Present
- Program Chair of the *International Donor Registry Conference*, London, 2014
- Scientific Director of the CIBMTR *Late Effects and QoL Committee*, 2014–2019
- Past-chair (and member) of the *S(P)EAR Committee* of the WMDA, 2014–2019
- Member of the NMDP *Histocompatibility Advisory Group*, September 2014–Present
- Co-chair of the *FACT-CIBMTR Data Audit Committee*, 2015–2021
- Co-chair of the *Research Methodology and Study Design Working Group* for the NIH BMT Late Effects Consensus Conference, 2015–2016

- Member of the *Steering Committee* (collaborator) for the NMDP:Engaging Patients in Developing a Patient-Centered Hematopoietic Cell Transplant Research Agenda (EAIN-2956), 2016–2017
- Member of the *External Advisory Board* for the Pediatric Proton Consortium Registry (PPCR), 2017–Present
- Member of the *IMPACT Clinical Trials Committee*, expert scientific panel for Leukaemia UK (UK charity), 2018–Present
- Expert review panel member for the *Canadian National Transplant Research Program*, 2018–Present
- President-elect of the *WMDA*, 2019–2021
- Chair of the *Donor Pillar* for the *WMDA*, 2019–2021
- *Steering Committee* member for the ASTCT Biobehavioral Research SIG, 2019–2021
- President of the *WMDA*, 2021–2023
- Member of the Cooperative Assessment of Late Effects for Sickle Cell Disease Curative Therapies (Coalesce) Advisory Board (U01), 2021 - Present

## RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

### Current Funding

Title: A Data Resource for Analyzing Blood and Marrow Transplants  
Source: NIH/NCI U24CA076518  
Role: Principal Investigator  
Dates: 9/15/2017 – 8/31/2024

Title: BMT Clinical Research Network Data Coordinating Center  
Source: NIH/NHLBI U24HL138660  
Role: Co-Investigator  
Dates: 9/15/2017 – 8/31/2024

Title: Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR)  
Source: NIH/NCI U24CA233032  
Role: Co-Investigator  
Dates: 9/1/2018 – 6/30/2023

Title: HRSA: Stem Cell Therapeutic Outcomes Database  
Source: HSH25020170006C  
Role: Co-Investigator and Research Director  
Dates: 9/27/2017 – 9/26/2022

Title: Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantation.  
Source: NCI R01CA215134  
Role: Co-Investigator  
Dates: 5/1/2017 – 4/30/2022

Title: Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell Donors  
Source: NIH R01HL131731  
Role: Co-Investigator

Dates: 1/06/2018 – 12/31/2022

**Pending awards**

Title: DCC for 1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia  
Source: NHLBI U24 HL157560-01  
Role: Principal Investigator  
Dates: 3/1/2022 – 6/30/2028

**Completed funding**

Title: Incorporating patient reported outcomes into individualized prognostication tools for survival and quality of life in transplant patients.  
Source: NHLBI R21HL140314  
Role: Principal Investigator  
Dates: 8/1/2018 – 6/30/2020

Title: Building infrastructure for PRO collection  
Source: ONR N00014-17-1-2850  
Role: Co-Investigator  
Dates: 3/1/2018 – 9/30/2020

Title: Quality of Life in Older Patients Receiving Hematopoietic Cell Transplantation for Blood Disorders  
Source: MCW Cancer Center Pilot Grant  
Role: Principal Investigator  
Dates: 12/1/2017 – 11/30/2019

Title: Bayesian Ensemble Models for Time to Event Data and Individualized Treatments  
Source: MCW Cancer Center Pilot Grant  
Role: Co-Investigator  
Dates: 06/01/2018 - 05/31/2019

**Prior funding (in the UK)**

2012 PI. **Next 7 steps**, survivorship post HCT  
2012–2015 Co-PI. **UK Stem Cell Foundation**. Immune Reconstitution in Cord Blood Transplantation  
2010–2012 PI. **Therakos**. MD Fellowship in Graft versus Host Disease  
2010–2014 PI. **Higher Education Funding Council for England (HEFCE)-Clinical Senior Lecturer (K-award equivalent)**  
2009–2010 PI. **Gilead** Antifungal Audit

**INVITED LECTURES/WORKSHOPS/PRESENTATIONS:**

**Local**

Mar 2018 QOL in Hematopoietic Cell Transplantation  
Department of Medicine Research Retreat, Milwaukee, USA

- Nov 2018 The first Anna Stadnicka Endowed speaker talk: A long journey of collaboration to improve transplant outcomes by 'clever' donor matching. With Katharina Fleischhauer, Milwaukee, Wisconsin, USA
- Aug 2019 The art and compassion of Medicine  
MCW white coat ceremony, Milwaukee, Wisconsin, USA

**National**

- June 2013 Donor Safety and Donor Selection Criteria  
NMDP Board Meeting, Las Vegas, USA
- June 2013 DPB1 T-Cell Epitope Matching in HSC Transplant  
Georgetown Lecture Series, Live Online
- Nov 2014 Patient Illness Session  
NMDP Council meeting, Minneapolis, USA
- Jan 2015 Haploidentical Transplants: trends and opportunities  
NMDP board meeting, Los Angeles, USA
- Feb 2015 How to select a donor and product for allogeneic HCT  
BMT tandem meeting, San Diego, USA
- Nov 2015 Non HLA donor factors for selection  
NMDP Council meeting, Minneapolis, USA
- Nov 2015 Diagnosis to Infusion  
NMDP Council meeting, Minneapolis, USA
- Feb 2016 How You Can Impact Clinical Practice through Participation: CIBMTR orientation, BMT tandem meeting, Honolulu, USA
- Feb 2016 Sorror Score: HCT-CI  
BMT tandem meeting, Honolulu, USA
- Mar 2016 Unrelated Donor Selection: HLA and other donor characteristics  
Memorial Sloan Kettering Cancer Center, New York, USA
- Dec 2016 Relapse in BMT  
BMT Winter workshop, San Diego, USA
- Feb 2017 Meet the experts: Donor selection  
BMT tandem meeting, Orlando, USA
- Feb 2017 Impacting Clinical Practice through Participation: CIBMTR orientation  
BMT tandem meeting, Orlando, USA
- May 2017 Center for International Blood and Marrow Transplant Research (CIBMTR),  
Pediatric Proton Consortium Registry, Boston, USA
- Aug 2017 Unrelated Donor Selection: HLA and other donor characteristics  
Oregon Health & Science University, Portland, USA
- Aug 2017 A resource for transplantation: Update of the Center for International Blood and Marrow Transplant Research (CIBMTR)  
Oregon Health & Science University, Portland, USA
- Nov 2017 Beyond HLA: What non-HLA characteristics are being considered in donor selection today?  
NMDP Council meeting, Minneapolis, USA
- Nov 2017 Why is haplo-transplantation a success?  
WMDA, Minneapolis, USA
- Feb 2018 Meet the experts: Donor selection  
BMT tandem meeting, Salt Lake City, USA
- Feb 2018 The impact of QOL on Hematopoietic Cell Transplantation  
BMT Tandem meeting, Salt Lake City, USA

Nov 2018	Donor and Cord Blood Selection Guidelines NMDP Council meeting, Minneapolis, USA
Feb 2019	Secondary Cancers post BMT TCT meeting, Houston, USA
April 2019	Patient-reported outcomes (PROs) in Hematopoietic Cell Transplantation Mayo Clinic Grand rounds, Phoenix, USA
July 2019	Patient-reported outcomes (PROs) in Hematopoietic Cell Transplantation Cleveland Clinic Grand rounds, Cleveland, USA
Sept 2019	What We Can Learn from International Regulatory Agencies and Registries: CIBMTR Cord Blood Connect meeting, Miami, USA
Sept 2019	How to Design a Multi-Center Trial with Little Funding and No Involvement of BMT CTN Cord Blood Connect meeting, Miami, USA
Oct 2019	Harnessing Technology, Big Data, and PROs to Reduce Toxicities and Symptoms After HCT and Cellular Therapy Keynote speaker: 2nd International Symposium on Biology, Prevention, and Treatment of Toxicities After Transplantation and Cellular Therapy, New York, USA
Dec 2019	CIBMTR As a Resource for Epidemiology Research for Myeloid Malignancy ASH, Orlando, USA
Feb 2020	Assuring the safety of volunteer unrelated donors TCT, Orlando, USA
May 2021	Matched and Mismatched unrelated donor transplantation New York Academy of Sciences, Frontiers in cancer Immunotherapy, Virtual
Oct 2021	Patient-specific selection of unrelated donors to optimize allogeneic hematopoietic cell transplant outcomes Grand Rounds, Dana Faber Cancer Center, virtual
Nov 2021	How I treat adult patients with no available matched donors NMDP One forum, virtual
Dec 2021	Improving Outcomes and Expanding Access to Unrelated Donor Transplants Grand rounds, University of Birmingham, Alabama, virtual

### **International**

Jan 2003	Mismatches and more mismatches, Current Issues in Haematopoietic Stem Cell Transplantation Royal Free Hospital, London, UK
July 2003	Potential immunosuppressive effects of CMV in unrelated stem cell transplantation Immunobiology Working Party, EBMT, Turkey
March 2005	The impact of HLA-DPB1 antigen and allele mismatches in unrelated donor HCT Immunobiology Working Party, EBMT, Prague, Czech Republic
June 2005	The Anthony Nolan Experience, outcome data on 423 transplant pairs and donor selection algorithms Topical Issues in Unrelated Donor Haematopoietic Stem Cell Transplants: a workshop convened by the Anthony Nolan trust, London, UK

- Feb 2006 Major Histocompatibility antigens: the clinical impact of HLA mismatches and donor selection strategies  
Immunogenetics in Haematology and Stem Cell Transplantation, Polish Society of Immunogenetics, Wroclaw, Poland
- March 2007 Factors impacting on the success of DLI in recipients of reduced-intensity conditioned transplants.  
Immunobiology Working Party, EBMT, Lyon, France
- April 2008 Finding a donor for stem cell transplantation: registries, regulations and outcomes  
Educational Day, Princess of Wales Hospital, Wales, UK
- May 2008 GvHD/GvL  
BSHI Spring Training Day, Birmingham, UK
- Aug 2008 The Role Of HLA-DPB1 In The Outcome Of Unrelated Donor Hematopoietic Stem Cell Transplantation  
The Reduced Intensity conditioning-indications, implications and outcomes  
Donor Lymphocytes Infusions, Second Transplants and Other Options For Preventing And Treating Disease Relapse Post transplantation  
23<sup>rd</sup> Current Course on Molecular Genetics, ASHI, Mexico City, Mexico
- Oct 2008 Understanding HLA and donor selection strategies  
BSBMT Educational Day, London, UK
- June 2009 Alternative donors and cord blood transplantation  
Haematological Malignancies, London, UK
- Oct 2009 Graft Identification Advisory Service (GIAS)  
Joint Symposium on Cord Blood Transplantation - Future Challenges, London, UK
- June 2010 Advances in transplantation  
Haematological Malignancies, London, UK
- June 2010 GCSF in normal donors  
GCSF symposium, Barcelona, Spain
- Aug 2010 The Role Of HLA-DPB1 In the Outcome Of Unrelated Donor Hematopoietic Stem Cell Transplantation  
Donor selection for transplantation  
Disease Relapse Post transplantation  
25<sup>th</sup> Current Course on Molecular Genetics, ASHI, Mexico City, Mexico
- Nov 2010 Alternative Donor Transplantation: historical and future perspective  
Taiwanese Society of Haematology, Taiwan  
Guangzhou, China
- Feb 2011 Vigilance and Surveillance in haematopoietic stem cell transplantation.  
NOTIFY project meeting, Bologna, Italy
- Apr 2011 Chronic GvHD: prevention, treatment options and outcomes  
THERAKOS corporate symposium  
EBMT, Paris, France
- May 2011 The best donor for transplantation.  
ESH-EBMT training course, La Baule, France
- June 2011 Donor selection strategies  
Southampton and Leeds, UK
- Feb 2012 Optimising unrelated donor selection: Development of GIAS  
Symposium on Alternative Donor Transplantation: The State of the Art, London, UK



Mar 2012	HSCT: The experiences of registries and future needs Legal and Ethical Challenges in HSCT, Basel, Switzerland
April 2012	The best donor for transplantation ESH-EBMT training course, Sofia, Bulgaria
April 2012	The safety of G-CSF in healthy donors Chugai Corporate Symposium, EBMT, Geneva, Switzerland
April 2012	A retrospective study of the impact of T cell epitope matching at HLA-DPB1 in recipients of unrelated donor hematopoietic cell transplant Immunobiology Working Group EBMT, Geneva, Switzerland
April 2012	Impact of stem cell source comparison between peripheral blood and bone marrow: Donor side Joint WMDA/EBMT session, EBMT, Geneva, Switzerland
May 2012	Adverse events reporting IDRC, Sydney, Australia
Sept 2012	Unrelated donors versus saviour siblings: debate Science Festival, Aberdeen, UK
Oct 2012	Biosimilars in paediatric practice Paediatric symposium, London, UK
Oct 2012	The use of biosimilars in haematology EBMT nurses' group, London, UK
April 2013	Are our increasing demands on donors justifiable? EBMT, London, UK
Sept 2013	Donor selection for transplantation UCT Bone Marrow Transplant Seminar, Cape Town, South Africa
Sept 2013	Donor care and management South African Bone Marrow Donor Registry 21 <sup>st</sup> Anniversary meeting, Cape Town, South Africa
Oct 2013	Donor safety and suitability for transplantation WBMT/WHO meeting, Brazil
Nov 2013	What do we know and what should we do about GI toxicity after stem cell transplantation: the role of the gut in GvHD GI and nutritional consequences of cancer treatment, London, UK
Nov 2013	Second allogeneic transplants BSBMT Education Day, London, UK
Mar 2014	Donor Issues EBMT, Milan, Italy
Dec 2014	Patient aspects of transplantation (Medical Basics) WMDA search co-ordinator certification program (WebEx)
May 2015	Donor Selection and Safety Canadian Bone Marrow Group meeting, Montreal, Canada
Aug 2016	Role of FACT-JACIE accreditation in HCT The 2nd Pujiang Symposium on Immunity & Transplantation, Shanghai, China
Sept 2016	Donor Safety and Donor Care vs Patient Needs South African Bone Marrow Registry, 2nd Academic Morning, Cape Town, South Africa
Sept 2016	Secondary Selection Criteria in Unrelated Donor Transplantation– Including Consideration of DPB1 and other non-HLA Factors South African Bone Marrow Registry, 2nd Academic Morning, Cape Town, South Africa

Nov 2016	Donor selection according to stem cell source 3rd International Workshop on Biology, Prevention and Treatment of Relapse after Stem Cell Transplantation, Hamburg, Germany
Nov 2016	Panel Discussion: Improving relapse data in registries 3rd International Workshop on Biology, Prevention and Treatment of Relapse after Stem Cell Transplantation, Hamburg, Germany
Mar 2017	CIBMTR-EBMT collaborations in late effects and QOL EBMT, Marseille, France
May 2018	CIBMTR: trends in outcomes 3 <sup>rd</sup> annual 'advancing immunomodulation' meeting, London, UK
May 2018	The impact of ECP and treatment alternatives on QOL and late effects The UK ECP patient pathway transformation team meeting, London, UK
May 2018	Return to work and patient-reported outcomes in CIBMTR Anthony Nolan survivorship nurses conference, London, UK
Aug 2018	QOL: How the right choices and complications influence Long term survivors? 22 <sup>nd</sup> Congress of the Brazilian Society of Bone Marrow Transplantation, Rio de Janeiro, Brazil
Aug 2018	State-of-the-art donor selection according to donor secondary characteristics and stem cell source 22 <sup>nd</sup> Congress of the Brazilian Society of Bone Marrow Transplantation, Rio de Janeiro, Brazil
Aug 2018	Related haploidentical donors versus matched unrelated donors 22 <sup>nd</sup> Congress of the Brazilian Society of Bone Marrow Transplantation, Rio de Janeiro, Brazil
Aug 2018	HLA and Donor information 22 <sup>nd</sup> Congress of the Brazilian Society of Bone Marrow Transplantation, Rio de Janeiro, Brazil
June 2019	Survivorship in Hematopoietic Cell Transplant patients – Late effects and quality of life, Winnipeg BMT unit grand rounds, Winnipeg, Canada
July 2019	HLA and Donor information 23 <sup>rd</sup> Congress of the Brazilian Society of Bone Marrow Transplantation, Brasilia, Brazil
July 2019	Donor Safety and WMDA perspective 23 <sup>rd</sup> Congress of the Brazilian Society of Bone Marrow Transplantation, Brasilia, Brazil
Aug 2019	Late complications after pediatric allogeneic Transplants 23 <sup>rd</sup> Congress of the Brazilian Society of Bone Marrow Transplantation, Brasilia, Brazil
Aug 2019	Impact of donor and cell source on relapse after alloHCT 23 <sup>rd</sup> Congress of the Brazilian Society of Bone Marrow Transplantation, Brasilia, Brazil
April 2020	ASTCT & CIBMTR Joint Webinar: Reporting to CIBMTR During the COVID-19 Pandemic Virtual platform
June 2020	Promoting donor care, WMDA Virtual platform
Dec 2020	A Stem Cell Donor for Every Patient Presidential Symposium, American Society of Hematology, Virtual
Feb 2021	CIBMTR PRO project TCT meeting, Virtual

Mar 2021	Do PROs predict HSCT outcome? Plenary session, EBMT, Virtual
Mar 2021	In the absence of a matched-sibling, who's the best alternative allogeneic donor? A matched unrelated donor, EBMT, Virtual
Mar 2021	Hematopoietic Cell Transplantation-Comorbidity Index 'Sorrow Score' EBMT, Virtual
April 2021	Mismatched volunteer unrelated donor EFI, Virtual
May 2021	Donor selection: Non-HLA related factors 2nd Argentine Congress on Hematopoietic Transplantation and Cell Therapy, Virtual
May 2021	Donor selection: Donor Safety 2nd Argentine Congress on Hematopoietic Transplantation and Cell Therapy, Virtual
Nov 2021	Mismatched Unrelated Donor Hematopoietic Cell Transplantation: improving outcomes and expanding access Anthony Nolan Graft selection Day, London, virtual

## **MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:**

### **Medical Students**

Antony Ibrahim, 2017-2020, Research mentor, 'Sleep aids in Bone Marrow Transplantation' (manuscript in preparation).

### **Fellows**

Matt Ehrhart, 2015-2016, research mentor, 'Survival of patients who develop solid tumors following hematopoietic stem cell transplantation' (published).

Neel Bhatt, 2016-2018, research mentor and Scholarship Oversight Committee (SOC) member, 'Post-transplantation employment status of adult survivors of childhood allogeneic hematopoietic cell transplant: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR)' (published).

Nicole Liberio, 5/2021-current, research mentor and SOC member, recipient of TL1 award for 'Impact of donor age in haplo-identical transplantation' (commencing study).

### **Faculty**

Soyoung Kim, 1/2017-12/2017, research mentor: American Cancer Society grant 'Variable selection for the case-cohort design with multiple diseases'.

Rachel Phelan, 2017 – current, research and career mentor.

Rachel Cusatis, 2020 – current, research and career mentor.

## **EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:**

**PhD Students Advised (all theses titles listed were granted by University College London, London, UK)**

Neema Mayor, 2010, Nucleotide-binding oligodimerisation domain containing 2/caspase recruitment domain family member 15 gene polymorphisms and their impact on the outcome of unrelated donor Haematopoietic Stem Cell transplantation.

Fiona Dignan, 2012, Novel strategies for managing Graft-versus-host Disease

Robert Lown, 2014, Factors Influencing the Provision of Unrelated Haematopoietic Stem Cell Donors.

Esteban Arrieta, 2014, Functional consequences of TGFB1 polymorphisms and their role in haematopoietic stem cell transplantation.

Annelies Billen, 2015, The impact of donor health and psychosocial factors on the donation experience and recovery.

Fuiyee Lee, 2015, The impact of CAMPATH on cord blood and peripheral blood cells

Chloe Anthias, 2016, Related haematopoietic progenitor cell donor care: the influence of current guidelines, and pathways to improvement

Vikesh Devlia, 2018, Immune reconstitution in cord blood transplantation.

## **BIBLIOGRAPHY**

### **Link to current publication list in NCBI (pubmed):**

<https://www.ncbi.nlm.nih.gov/myncbi/1Rwv3O8055w5B/bibliography/public/>

1. Cusatis R, Flynn KE, Vasu S, Pidala J, Muffly L, Uberti J, Tamari R, Mattila D, Mussetter A, Bruzauskas R, Chen M, Leckrone E, Myers J, Mau LW, Rizzo JD, Saber W, Horowitz M, Lee SJ, Burns LJ, **Shaw B**. Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry. *Transplant Cell Ther*. 2021 Oct 29:S2666-6367(21)01327-0. doi: 10.1016/j.jtct.2021.10.016. Online ahead of print.
2. Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, **Shaw BE**, Walters MC, Foley A, Devine SM, Horowitz MM. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. *Transplant Cell Ther*. 2021 Nov;27(11):885-907.
3. Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MM, Modi D, Grunwald MR, Nishihori T, Kuxhausen M, Fingerson S, McKallor C, Bashey A, Kasamon YL, Bolon YT, Saad A, McGuirk JP, Paczesny S, Gadalla SM, Marsh SG, **Shaw BE**, Spellman SR, Lee SJ, Petersdorf EW. HLA Informs Risk Predictions after Haploidentical Stem Cell Transplantation with Post-transplantation Cyclophosphamide. *Blood*. 2021 Nov 1;. doi: 10.1182/blood.2021013443. [Epub ahead of print] PubMed PMID: 34724567.
4. Hough RE, Lopes A, Patrick P, Russell NH, Raj K, Tholouli E, Snowden JA, Collin M, El-Mahidi N, Lawrie A, Clifton-Hadley L, Veys P, Craddock CF, Mackinnon S, Cook G, **Shaw BE**, Marks DI. Primary graft failure, but not relapse, may be identified by early chimerism following double cord unit transplantation. *Blood Adv*. 2021 Oct 26;. doi: 10.1182/bloodadvances.2021005106. [Epub ahead of print] PubMed PMID: 34700343.
5. Kelly DL, Syrjala K, Taylor M, Rentscher KE, Hashmi S, Wood WA, Jim H, Barata A, Flynn KE, Burns LJ, **Shaw BE**, Petersdorf E, Yero AC, Emmrich AD, Morris KE, Costanzo ES, Knight JM. Biobehavioral Research and Hematopoietic Stem Cell

- Transplantation: Expert Review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and Cellular Therapy. *Transplant Cell Ther.* 2021 Sep;27(9):747-757.
6. Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjaneh A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau LW, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, Battiwalla M, Schoemans H, Hamilton B, Buchbinder D, Phelan R, **Shaw B**. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. *Transplant Cell Ther.* 2021 Aug;27(8):679.e1-679.e8. doi: 10.1016/j.jtct.2021.04.013. Epub 2021 Apr 22. PubMed PMID: 33895402; PubMed Central PMCID: PMC8425287.
  7. Logan BR, Maiers MJ, Sparapani RA, Laud PW, Spellman SR, McCulloch RE, **Shaw BE**. Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning. *JCO Clin Cancer Inform.* 2021 May;5:494-507.
  8. **Shaw BE**, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. *J Clin Oncol.* 2021 Jun 20;39(18):1971-1982
  9. Hsu JW, Farhadfar N, Murthy H, Logan BR, Bo-Subait S, Frey N, Goldstein SC, Horowitz MM, Lazarus H, Schwanke JD, Shah NN, Spellman SR, Switzer GE, Devine SM, **Shaw BE**, Wingard JR. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. *Transplant Cell Ther.* 2021 Jun;27(6):507-516.
  10. Seftel MD, Chitphakdithai P, Miller JP, Kobusingye H, Logan BR, Linenberger M, Artz AS, Haight AE, Jacobsohn DA, Litzow MR, Magalhaes-Silverman M, Selby GB, Vusirikala M, Horowitz MM, Switzer GE, Confer DL, **Shaw BE**, Pulsipher MA. Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study. *Transplant Cell Ther.* 2021 Apr;27(4):352.e1-352.e5. doi: 10.1016/j.jtct.2021.01.009. Epub 2021 Jan 15. PMID: 33836890
  11. Mayor NP, Wang T, Lee SJ, Kuxhausen M, Vierra-Green C, Barker DJ, Auletta J, Bhatt VR, Gadalla SM, Gragert L, Inamoto Y, Morris GP, Paczesny S, Reshef R, Ringdén O, **Shaw BE**, Shaw P, Spellman SR, Marsh SGE. Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. *J Clin Oncol.* 2021 Jul 20;39(21):2397-2409.
  12. Panch SR, Logan B, Sees JA, Bo-Subait S, Savani B, Shah NN, Hsu JW, Switzer G, Lazarus HM, Anderlini P, Hematti P, Confer D, Pulsipher MA, **Shaw BE**, Stroncek DF. Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. *Transplant Cell Ther.* 2021 Mar 9:S2666-6367(21)00751-X. doi: 10.1016/j.jtct.2021.03.008. Online ahead of print. PMID: 33823169
  13. Worel N, **Shaw BE**, Aljurf M, Koh M, Seber A, Weisdorf D, Schwartz J, Galeano S, Kodera Y, Eldridge PW, Hashmi S, Atsuta Y, Szer J, Saber W, Niederwieser D, Greinix HT; Worldwide Network for Blood & Marrow Transplantation. Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide

- Network for Blood & Marrow Transplantation. *Transplant Cell Ther.* 2021 Mar;27(3):270.e1-270.e6. doi: 10.1016/j.jtct.2020.11.019. Epub 2020 Dec 15. PMID: 33781537
14. Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, Dandoy C, Gauthier J, Gowda L, Perales MA, Seropian S, **Shaw BE**, Tuschi EE, Zeidan AM, Riches ML, Shah GL. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. *Lancet Haematol.* 2021 Mar;8(3):e185-e193. doi: 10.1016/S2352-3026(20)30429-4. Epub 2021 Jan 19. PMID: 33482113
  15. Hong S, Brazauskas R, Hebert KM, Ganguly S, Abdel-Azim H, Diaz MA, Beattie S, Ciurea SO, Szwajcer D, Badawy SM, Gratwohl AA, LeMaistre C, Aljurf MDSM, Olsson RF, Bhatt NS, Farhadfar N, Yared JA, Yoshimi A, Seo S, Gergis U, Beitinjaneh AM, Sharma A, Lazarus H, Law J, Ulrickson M, Hashem H, Schoemans H, Cerny J, Rizzieri D, Savani BN, Kamble RT, **Shaw BE**, Khera N, Wood WA, Hashmi S, Hahn T, Lee SJ, Rizzo JD, Majhail NS, Saber W. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. *Cancer.* 2020 Oct 21. doi: 10.1002/cncr.33232. Online ahead of print.
  16. Farhadfar N, Burns LJ, Mupfudze T, **Shaw BE**, Bollard CM, Devine SM, Horowitz MM, Jones RJ, Murthy HS, Wingard JR, Lee SJ. Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. *Transplant Cell Ther.* 2021 Feb;27(2):183.e1-183.e7. doi: 10.1016/j.bbmt.2020.10.006. Epub 2020 Oct 9. PMID: 33045387
  17. Dehn J, Chitphakdithai P, **Shaw BE**, McDonald AA, Devine SM, Burns LJ, Spellman S. Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease, and Search Prognosis. *Transplant Cell Ther.* 2021 Feb;27(2):184.e1-184.e13. doi: 10.1016/j.bbmt.2020.10.004. Epub 2020 Oct 10. PMID: 33045385
  18. Switzer GE, Bruce JG, Kiefer DM, Kobusingye H, Abebe KZ, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, **Shaw BE**, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, Litzow MR, Pulsipher MA. Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. *Biol Blood Marrow Transplant.* 2020 Dec;26(12):2365-2371.
  19. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, **Shaw BE**, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant.* 2020 Oct;26(10):1876-1885.
  20. Berro M, Chhabra S, Piñana JL, Arbelbide J, Rivas MM, Basquiera AL, Vitriu A, Requejo A, Milovic V, Yantorno S, Bentolila G, Garcia JJ, Castro M, Palmer S, Saslavsky M, Duarte P, Cerutti A, Jarchum G, Tisi Baña M, Thapa B, Solano C, Sureda A, Rovira M, **Shaw BE**, Kusminsky G; Grupo Argentino de Trasplante de Médula Ósea y Terapia Celular (GATMO-TC). Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score. *Biol Blood Marrow Transplant.* 2020 Oct;26(10):1828-1832.
  21. Chhabra S, Abedin S, Graham MB, Ferrer Marrero TM, Hari PN, **Shaw BE**. Letter to the Editor Regarding "Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation". *Biol Blood Marrow Transplant.* 2020 Sep;26(9):e241-e242.
  22. Nacheva E, Ahyee T, Addada J, Navarette C, Pamphilon D, Regan F, Pawson R, Szydlo R, Goldman J, Mackinnon S, **Shaw BE**, Madrigal A. Absence of damaging effects of

- stem cell donation in unrelated donors assessed by FISH and gene variance screening. *Bone Marrow Transplant.* 2020 Jul;55(7):1290-1296.
23. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, **Shaw BE**, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. *Biol Blood Marrow Transplant.* 2020 Aug;26(8):e177-e182.
  24. Kahn JM, Brazauskas R, Tecca HR, Bo-Subait S, Buchbinder D, Battiwala M, Flowers MED, Savani BN, Phelan R, Broglie L, Abraham AA, Keating AK, Daly A, Wirk B, George B, Alter BP, Ustun C, Freytes CO, Beitinjaneh AM, Duncan C, Copelan E, Hildebrandt GC, Murthy HS, Lazarus HM, Auletta JJ, Myers KC, Williams KM, Page KM, Vrooman LM, Norkin M, Byrne M, Diaz MA, Kamani N, Bhatt NS, Rezvani A, Farhadfar N, Mehta PA, Hematti P, Shaw PJ, Kamble RT, Schears R, Olsson RF, Hayashi RJ, Gale RP, Mayo SJ, Chhabra S, Rotz SJ, Badawy SM, Ganguly S, Pavletic S, Nishihori T, Prestidge T, Agrawal V, Hogan WJ, Inamoto Y, **Shaw BE**, Satwani P. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. *Blood Adv.* 2020 May 12;4(9):2084-2094.
  25. Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, **Shaw BE**, Weisdorf DJ, Horowitz MM. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. *Biol Blood Marrow Transplant.* 2020 Jul;26(7):e161-e166
  26. Salit RB, Lee SJ, Burns LJ, **Shaw BE**, Majhail NS, Bhatt NS, Wood WA, Syrjala KL. Return-to-Work Guidelines and Programs for Post-Hematopoietic Cell Transplantation Survivors: An Initial Survey. *Biol Blood Marrow Transplant.* 2020 Aug;26(8):1520-1526.
  27. Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O' Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, **Shaw BE**, Wingard JR. Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. *Bone Marrow Transplant.* 2020 Nov;55(11):2121-2131.
  28. Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, **Shaw BE**, Weisdorf D, Devine SM, Horowitz MM. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. *Biol Blood Marrow Transplant.* 2020 Jul;26(7):1312-1317.
  29. Bultitude WP, Schellekens J, Szydlo RM, Anthias C, Cooley SA, Miller JS, Weisdorf DJ, **Shaw BE**, Roberts CH, Garcia-Sepulveda CA, Lee J, Pearce RM, Wilson MC, Potter MN, Byrne JL, Russell NH, MacKinnon S, Bloor AJ, Patel A, McQuaker IG, Malladi R, Tholouli E, Orchard K, Potter VT, Madrigal JA, Mayor NP, Marsh SGE. Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. *Bone Marrow Transplant.* 2020 Oct;55(10):1975-1984.
  30. Lee CJ, Kim S, Tecca HR, Bo-Subait S, Phelan R, Brazauskas R, Buchbinder D, Hamilton BK, Battiwalla M, Majhail NS, Lazarus HM, Shaw PJ, Marks DI, Litzow MR, Chhabra S, Inamoto Y, DeFilipp Z, Hildebrandt GC, Olsson RF, Kasow KA, Liesveld JL, Rotz SJ, Badawy SM, Bhatt NS, Yared JA, Page KM, Arellano ML, Kent M, Farhadfar N, Seo S, Hematti P, Freytes CO, Rovó A, Ganguly S, Nathan S, Burns L, **Shaw BE**, Muffly

- LS. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. *Blood Adv.* 2020 Mar 24;4(6):983-992.
31. Cusatis RN, Tecca HR, D'Souza A, **Shaw BE**, Flynn KE. Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. *Cancer.* 2020 Jun 1;126(11):2679-2686.
  32. Seftel MD, Kuxhausen M, Burns L, Chitphakdithai P, Confer D, Kiefer D, Lee S, Logan B, O'Donnell P, Pulsipher M, Shah NN, Switzer G, **Shaw BE**. clonal hematopoiesis in related allogeneic transplant donors: implications for screening and management. *Biol Blood Marrow Transplant.* 2020 Mar 5. pii: S1083-8791(20)30108-7.
  33. Farhadfar N, Hsu JW, Logan BR, Sees JA, Chitphakdithai P, Sugrue MW, Abdel-Azim H, Anderlini PN, Bredeson C, Chhabra S, Diaz MA, Ganguly S, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Lynch DK, Murthy HS, Olsson RF, Papari M, Przepiorka D, Savani BN, Schears R, Seo S, Solh MM, Spitzer T, Yared JA, Pulsipher MA, Shah NN, Switzer GE, Confer DL, **Shaw BE**, Wingard JR. Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. *Blood Adv.* 2020 Feb 25;4(4):706-716
  34. Hsu JW, **Shaw BE**, Kim S, Logan BR, Sees JA, Confer DL, Pulsipher MA, Shah N, Switzer GE, Abidi MH, Ahmed IA, Anderlini PN, Bredeson C, Chhabra S, Dandoy CE, Diaz MA, Farhadfar N, Ganguly S, Gergis U, Hale GA, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Murthy HS, Olsson RF, Savani BN, Schears R, Seo S, Solh M, Spitzer T, Steinberg A, Sugure M, Warkentin P, Wingard JR. Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. *Biol Blood Marrow Transplant.* 2020 Jun;26(6):1210-1217.
  35. Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, **Shaw BE**, Hamadani M, Hari PN. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. *Biol Blood Marrow Transplant.* 2020 May;26(5):893-901.
  36. Wong WH, Bhatt S, Trinkaus K, Pusic I, Elliott K, Mahajan N, Wan F, Switzer GE, Confer DL, DiPersio J, Pulsipher MA, Shah NN, Sees J, Bystry A, Blundell JR, **Shaw BE**, Druley TE. Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. *Sci Transl Med.* 2020 Jan 15;12(526).
  37. Buchbinder D, Brazauskas R, Bo-Subait K, Ballen K, Parsons S, John T, Hahn T, Sharma A, Steinberg A, D'Souza A, Kumar AJ, Yoshimi A, Wirk B, **Shaw B**, Freytes C, LeMaistre C, Bredeson C, Dandoy C, Almaguer D, Marks DI, Szwajcer D, Hale G, Schouten H, Hashem H, Schoemans H, Murthy HS, Lazarus HM, Cerny J, Tay J, Yared JA, Adekola K, Schultz KR, Lehmann L, Burns L, Aljurf M, Diaz MA, Majhail N, Farhadfar N, Kamble R, Olsson R, Schears R, Seo S, Beattie S, Chhabra S, Savani BN, Badawy S, Ganguly S, Ciurea S, Marino S, Gergis U, Kuwatsuka Y, Inamoto Y, Khera N, Hashmi S, Wood W, Saber W. Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. *Biol Blood Marrow Transplant.* 2020 Mar;26(3):553-561.
  38. Anthias C, **Shaw BE**, Bruce JG, Confer DL, Abress LK, Dew MA, Billen A, O'Leary A, Braund H, Switzer GE. The role of race/ethnicity in donor decisions about unrelated hematopoietic progenitor cell donation; Exploring reasons for higher attrition among racial/ethnic minorities. *Biol Blood Marrow Transplant.* 2020 Mar;26(3):593-599.



39. Herr MM, Curtis RE, Tucker MA, Tecca HR, Engels EA, Cahoon EK, Battiwalla M, Buchbinder D, Flowers ME, Brazauskas R, **Shaw BE**, Morton LM. Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation. *J Am Acad Dermatol.* 2020 Sep;83(3):762-772.
40. Ruark J, Mullane E, Cleary N, Cordeiro A, Bezerra ED, Wu V, Voutsinas J, **Shaw BE**, Flynn K, Lee SJ, Turtle CJ, Maloney DG, Fann JR, Bar M. Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor-T Cell Therapy. *Biol Blood Marrow Transplant.* 2020 Jan;26(1):34-43.
41. Pidala J, Mupfudze TG, Payton T, Barker J, Perales MA, **Shaw BE**, Fernández-Viña M, Burns LJ, Dehn J. Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program. *Biol Blood Marrow Transplant.* 2019 Dec;25(12):2501-2506.
42. Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, **Shaw BE**, D'Souza A. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. *Amyloid.* 2019 Dec;26(4):210-215.
43. Dehn J, Spellman S, Hurley CK, **Shaw BE**, Barker JN, Burns LJ, Confer DL, Eapen M, Fernandez-Vina MA, Hartzman R, Maiers M, Marino SR, Mueller C, Perales MA, Rajalingam R, Pidala J. Selection of Unrelated Donors and Cord Blood Units for Hematopoietic Cell Transplantation: Guidelines from NMDP/CIBMTR. *Blood.* 2019 Sep 19;134(12):924-934.
44. Mayor NP, Hayhurst JD, Turner TR, Szydlo RM, **Shaw BE**, Bultitude WP, Sayno JR, Tavarozzi F, Latham K, Anthias C, Robinson J, Braund H, Danby R, Perry J, Wilson MC, Bloor AJ, McQuaker IG, MacKinnon S, Marks DI, Pagliuca A, Potter MN, Potter VT, Russell NH, Thomson KJ, Madrigal JA, Marsh SGE. A reply to Hurley et al. regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. *Biol Blood Marrow Transplant.* 2019 Aug;25(8):e270-e271.
45. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. 4-Locus high-resolution HLA allele and haplotype frequencies in Amerindians from Costa Rica. *Hum Immunol. Hum Immunol.* 2019 Jul;80(7):409-410.
46. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Órlich-Pérez P, Arrieta-Molina G, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. 5-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from the Central Valley. *Hum Immunol.* 2019 Jul;80(7):413-414
47. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Arrieta-Molina G, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. 4-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from Guanacaste. *Hum Immunol.* 2019 Jul;80(7):415-416.
48. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Arrieta-Molina G, Grant S, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. 4-Locus high-resolution HLA allele and haplotype frequencies in Costa Ricans from African-Caribbean descent. *Hum Immunol.* 2019 Jul;80(7):411-412.
49. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Moreira-Espinoza MJ, Paredes-Carias E, Vanegas-Padilla Y, Salazar-Sánchez L, Madrigal JA, Marsh SGE, **Shaw BE**. 4-Locus high-resolution HLA allele and haplotype frequencies in admixed population from Nicaragua. *Hum Immunol.* 2019 Jul;80(7):417-418.
50. **Shaw BE**, D'Souza A, Lee SJ. Importance of Assessing Patient-Reported Outcomes With Salvage Autologous Transplantation in Relapsed Multiple Myeloma. *J Clin Oncol.* 2019 Jul 1;37(19):1598-1600.

51. Wiener L, Hoag JA, Pelletier W, Shah NN, **Shaw BE**, Pulsipher MA, Bruce J, Bader P, Willasch AM, Dalissier A, Guilcher G, Anthias C, Confer DL, Sees JA, Logan B, Switzer GE. Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors. *Bone Marrow Transplant*. 2019 Nov;54(11):1780-1788.
52. Mayor NP, Hayhurst JD, Turner TR, Szydlo RM, **Shaw BE**, Bultitude WP, Sayno JR, Tavarozzi F, Latham K, Anthias C, Robinson J, Braund H, Danby R, Perry J, Wilson MC, Bloor AJ, McQuaker IG, MacKinnon S, Marks DI, Pagliuca A, Potter MN, Potter VT, Russell NH, Thomson KJ, Madrigal JA, Marsh SGE. Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study. *Biol Blood Marrow Transplant*. 2019 Mar;25(3):443-450.
53. Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, **Shaw BE**, Miller JP, Hosoba S, Waller EK, Devine SM. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. *Blood Adv*. 2019 Mar 26;3(6):875-883.
54. Schoemans HM, Finn L, Foster J, Roche-Green A, Bevans M, Kullberg S, Lee E, Sargeant C, Schatz BA, Scheeler K, **Shaw BE**, Shereck E, Murphy EA, Burns LJ, Schmit-Pokorny K. A Conceptual Framework and Key Research Questions in Educational Needs of Blood and Marrow Transplant Patients, Caregivers and Families. *Biol Blood Marrow Transplant*. 2019 Jul;25(7):1416-1423.
55. Aljurf M, Weisdorf D, Alfraih F, Szer J, Müller C, Confer D, Hashmi S, Kröger N, **Shaw BE**, Greinix H, Kharfan-Dabaja MA, Foeken L, Seber A, Ahmed S, El-Jawahri A, Al-Awwami M, Atsuta Y, Pasquini M, Hanbali A, Alzahrani H, Okamoto S, Gluckman E, Mohty M, Koderá Y, Horowitz M, Niederwieser D, El Fakih R. "Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries". *Bone Marrow Transplant*. 2019 Aug;54(8):1179-1188.
56. Prokopishyn NL, Logan BR, Kiefer DM, Sees JA, Chitphakdithai P, Ahmed IA, Anderlini PN, Beitinjaneh AM, Bredeson C, Cerny J, Chhabra S, Daly A, Diaz MA, Farhadfar N, Frangoul HA, Ganguly S, Gastineau DA, Gergis U, Hale GA, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Murthy HS, Norkin M, Olsson RF, Papari M, Savani BN, Szer J, Waller EK, Wirk B, Yared JA, Pulsipher MA, Shah NN, Switzer GE, O'Donnell PV, Confer DL, **Shaw BE**. The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. *Biol Blood Marrow Transplant*. 2019 Jul;25(7):1325-1330.
57. **Shaw BE**. Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective? *Curr Hematol Malig Rep*. 2019 Feb;14(1):22-30.
58. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Ball ED, Bolwell BJ, Bunin NJ, Cheerva A, Delgado DC, Dvorak CC, Gillio AP, Hahn TE, Hale GA, Haight AE, Hayes-Lattin BM, Kasow KA, Linenberger M, Magalhaes-Silverman M, Mori S, Prasad VK, Quigg TC, Sahdev I, Schriber JR, Shenoy S, Tse WT, Yanik GA, Navarro WH, Horowitz MM, Confer DL, **Shaw BE**, Switzer GE. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. *Biol Blood Marrow Transplant*. 2019 May;25(5):955-964.
59. Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, Al-Khinji A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP,

- Ganguly S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, **Shaw BE**, Valdés-Sanz N. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. *Bone Marrow Transplant*. 2019 May;54(5):648-661.
60. Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini MT, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E, Lee C, Nathan S, Penack O, Prasad P, Rotz S, Rovó A, Yared J, Pavletic S, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, **Shaw BE**, Petriček I. Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. *Bone Marrow Transplant*. 2019 May;54(5):662-673.
61. Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, Ahmed A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP, Ganguly S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers ME, **Shaw BE**, Valdés-Sanz N. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. *Biol Blood Marrow Transplant*. 2019 May;25(5):e145-e154.
62. Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Stanghellini MTL, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E, Lee C, Nathan S, Penack O, Prasad P, Rotz S, Rovó A, Yared J, Pavletic S, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers ME, **Shaw BE**, Petriček I. Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. *Biol Blood Marrow Transplant*. 2019 Feb;25(2):e46-e54.
63. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, **Shaw BE**. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors. *Haematologica*. 2019 Apr;104(4):844-854.
64. Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ,

- Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, **Shaw BE**, Confer DL. The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe). *Biol Blood Marrow Transplant*. 2019 Apr;25(4):699-711.
65. Bhatt NS, Brazauskas R, Tecca HR, Carreras J, Burns LJ, Phelan R, Salit RB, Syrjala KL, Talano JM, **Shaw BE**. Post-transplantation employment status of adult survivors of childhood allogeneic hematopoietic cell transplant: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR). *Cancer*. 2019 Jan 1;125(1):144-152.
66. Norkin M, **Shaw BE**, Brazauskas R, Tecca HR, Leather HL, Gea-Banacloche J, Kamble R, DeFilipp Z, Jacobsohn DA, Ringden O, Inamoto Y, Kasow K, Buchbinder D, Shaw P, Hematti P, Schears R, Badawy SM, Lazarus HM, Bhatt N, Horn B, Chhabra S, Page K, Hamilton B, Hildebrandt GC, Yared JA, Agrawal V, Beitinjaneh A, Majhail N, Kindwall-Keller T, Olsson RF, Schoemans H, Gale RP, Ganguly S, Ahmed I, Schouten HC, Liesveld J, Khera N, Steinberg A, Shah AJ, Solh M, Marks DI, Rybka W, Aljurf M, Dietz AC, Gergis U, George B, Seo S, Flowers MED, Battiwalla M, Savani BN, Riches ML, Wingard JR. Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplant. *Biol Blood Marrow Transplant*. 2019 Feb;25(2):362-368.
67. Pahnke S, Egeland T, Halter J, Hägglund H, **Shaw BE**, Woolfrey AE, Szer J; Working Group Medical of the World Marrow Donor Association. Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. *Bone Marrow Transplant*. 2019 Jun;54(6):858-866.
68. Liang J, Lee SJ, Storer BE, **Shaw BE**, Chow EJ, Flowers ME, Krakow EF, Bar M, Syrjala KL, Salit RB, Kurukulasuriya CE, Jim HSL. Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal Caregivers. *Biol Blood Marrow Transplant*. 2019 Jan;25(1):145-150.
69. La Casta AH, **Shaw BE**, Anthias C, Bruce JG, Pastorek G, Billen A, O'Leary A, Switzer GE. Motives for joining an unrelated HSC donor registry: description, categorization, and association with donor availability. *Bone Marrow Transplant*. 2019 Mar;54(3):425-431.
70. Radivoyevitch T, Dean RM, **Shaw BE**, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. *Leuk Res*. 2018 Nov;74:130-136.
71. Arrieta-Bolaños E, Crivello P, **Shaw BE**, Ahn KW, Wang HL, Verneris MR, Hsu KC, Pidala J, Lee SJ, Fleischhauer K, Spellman SR. In silico prediction of nonpermissive

- HLA-DPB1 mismatches in unrelated HCT by functional distance. *Blood Adv.* 2018 Jul 24;2(14):1773-1783.
72. Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, Ahn KW, **Shaw BE**, Kletzel M, Olszewski M, Khan S, Meshinchi S, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour A, Kasow KA, Gillio AP, Haight AE, Bhatia M, Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano JA, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. *Biol Blood Marrow Transplant.* 2018 Oct;24(10):2040-2046.
  73. Bhatt NS, Brazauskas R, Tecca HR, Vogel J, Mattila D, Lee SJ, Horowitz MM, Rizzo JD, **Shaw BE**. Female Sex is Associated With Poor Health-related Quality of Life in Children at 12 Months Post-Hematopoietic Cell Transplantation. *JJ Pediatr Hematol Oncol.* 2019 Apr;41(3):233-237.
  74. Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, **Shaw BE**, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ; EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the "EBMT-NIH (National Institutes of Health)-CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force". EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. *Bone Marrow Transplant.* 2018 Nov;53(11):1401-1415.
  75. Lee SJ, Onstad L, Chow EJ, **Shaw BE**, Jim HSL, Syrjala KL, Baker KS, Buckley S, Flowers ME. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. *Haematologica.* 2018 Sep;103(9):1535-1541.
  76. Fleischhauer K, Hsu KC, **Shaw BE**. Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection. *Bone Marrow Transplant.* 2018 Dec;53(12):1498-1507.
  77. Nemecek ER, Hilger RA, Adams A, **Shaw BE**, Kiefer D, Le-Rademacher J, Levine JE, Yanik G, Leung W, Talano JA, Haut P, Delgado D, Kapoor N, Petrovic A, Adams R, Hanna R, Rangarajan H, Dalal J, Chewning J, Verneris MR, Epstein S, Burroughs L, Perez-Albuerne ED, Pulsipher MA, Delaney C. Treosulfan, Fludarabine and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: a Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. *Biol Blood Marrow Transplant.* 2018 Aug;24(8):1651-1656.
  78. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE, Órlich-Pérez P, Moreira-Espinoza MJ, Paredes-Carias E, Vanegas-Padilla Y, Salazar-Sánchez L, Alejandro Madrigal J, Marsh SGE, **Shaw BE**. High-resolution HLA allele and haplotype frequencies in majority and minority populations of Costa Rica and Nicaragua: differential admixture proportions in neighboring countries. *HLA.* 2018 Jun;91(6):514-529.
  79. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, **Shaw BE**, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. *Biol Blood Marrow Transplant.* 2018 Aug;24(8):1664-1670.

80. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, **Shaw BE**, D'Souza A. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. *Bone Marrow Transplant*. 2018 Sep;53(9):1210-1213.
81. Duncan CN, Brazauskas R, Huang J, **Shaw BE**, Majhail NS, Savani BN, Flowers MED, Battiwalla M, Beebe K, Dietz AC, Dvorak CC, Giller R, Jacobsohn DA, Kletzel M, Martin PL, Nemecek ER, Nuechterlein B, Talano JA, Pulsipher MA, Baker KS. Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2018 Oct;53(10):1278-1287.
82. D'Souza A, Millard H, Knight J, Brazauskas R, Lee SJ, Flynn KE, Rizzo JD, **Shaw BE**. Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2018 Aug;53(8):1079-1082.
83. **Shaw BE**, Logan BR, Spellman SR, Marsh SGE, Robinson J, Pidala J, Hurley C, Barker J, Maiers M, Dehn J, Wang H, Haagenson M, Porter D, Petersdorf EW, Woolfrey A, Horowitz MM, Verneris M, Hsu KC, Fleischhauer K, Lee SJ. Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. *Biol Blood Marrow Transplant*. 2018 May;24(5):1049-1056.
84. Burns LJ, Abbetti B, Arnold SD, Bender J, Doughtie S, El-Jawahiri A, Gee G, Hahn T, Horowitz MM, Johnson S, Juckett M, Krishnamurthi L, Kullberg S, LeMaistre CF, Loren A, Majhail NS, Murphy EA, Rizzo D, Roche-Green A, Saber W, Schatz BA, Schmit-Pokorny K, **Shaw BE**, Syrjala KL, Tierney DK, Ullrich C, Vanness DJ, Wood WA, Denzen EM. Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2018 Jun;24(6):1111-1118.
85. Andermann T, Peled J, Ho C, Reddy P, Riches M, Storb R, Teshima T, van den Brink M, Alousi A, Balderman S, Chiusolo P, Clark W, Holler E, Howard A, Kean L, Koh A, McCarthy P, McCarty J, Mohty M, Nakamura R, Rezvani K, Segal B, **Shaw B**, Shpall E, Sung A, Weber D, Whangbo J, Wingard J, Wood W, Perales MA, Jenq R, Bhatt A; Blood and Marrow Transplant Clinical Trials Network. Microbiome-Host Interactions in Hematopoietic Stem Cell Transplant Recipients. *Biol Blood Marrow Transplant*. 2018 Jul;24(7):1322-1340.
86. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, **Shaw B**, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft versus host disease: low incidence of lower gastrointestinal tract disease. *Haematologica*. 2018 Apr;103(4):717-727.
87. Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B, **Shaw BE**. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. *Bone Marrow Transplant*. 2018 May;53(5):535-555.
88. **Shaw BE**. Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint. *Blood Adv*. 2017 Feb 14;1(6):401-406.

89. Myers RM, Hill BT, **Shaw BE**, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. *Cancer*. 2018 Feb 15;124(4):816-825.
90. **Shaw BE**, Syrjala KL, Onstad LE, Chow EJ, Flowers ME, Jim H, Baker KS, Buckley S, Fairclough DL, Horowitz MM, Lee SJ. PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. *Cancer*. 2018 Feb 15;124(4):841-849.
91. Billen A, Madrigal JA, Scior K, **Shaw BE**, Strydom A. Donation of peripheral blood stem cells to unrelated strangers: A thematic analysis. *PLoS One*. 2017 Oct 25;12(10):e0186438.
92. Stroncek DF, **Shaw BE**, Logan BR, Kiefer DM, Savani BN, Anderlini P, Bredeson CN, Hematti P, Ganguly S, Diaz MA, Abdel-Azim H, Ahmed I, Maharaj D, Seftel M, Beitinjaneh A, Seo S, Yared JA, Halter J, O'Donnell PV, Hale GA, DeFilipp Z, Lazarus H, Liesveld JL, Zhou Z, Munshi P, Olsson RF, Kasow KA, Szer J, Switzer GE, Chitphakdithai P, Shah N, Confer DL, Pulsipher MA. Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. *Biol Blood Marrow Transplant*. 2018 Jan;24(1):175-184.
93. Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, **Shaw BE**. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2018 Feb;24(2):228-241.
94. **Shaw BE**, Brazauskas R, Millard HR, Fonstad R, Flynn KE, Abernethy A, Vogel J, Petroske C, Mattila D, Drexler R, Lee SJ, Horowitz MM, Rizzo JD. Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. *Cancer*. 2017 Dec 1;123(23):4687-4700.
95. Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, **Shaw BE**, Shahir K, Banerjee A, Drobyski WR. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. *Biol Blood Marrow Transplant*. 2017 Nov;23(11):1955-1960.
96. Jerkins JH, Hamadani M, Zook F, Epperla N, **Shaw BE**, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN. Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. *Am J Hematol*. 2017 Oct;92(10): E610-E611.
97. Berro M, Arbelbide JA, Rivas MM, Basquiera AL, Ferini G, Vitriu A, Foncuberta C, Escobar NF, Requejo A, Milovic V, Yantorno S, Szlagoswki M, Rolon JM, Bentolila G, Garcia JJ, Garcia P, Caeiro G, Castro M, Jaimovich G, Palmer S, Trucco JI, Bet LA, **Shaw BE**, Kusminsky GD. HCT-CI Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2017 Oct;23(10):1646-1650.

98. Fleischhauer K, **Shaw BE**. HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities. *Blood*. 2017 Aug 31;130(9):1089-1096.
99. Switzer GE, Bruce J, Pastorek G, Kiefer DM, Kobusingye H, Drexler R, Besser RAM, Confer DL, Horowitz MM, King RJ, **Shaw BE**, van Walraven SM, Wiener L, Packman W, Varni JW, Pulsipher MA. Parent versus child donor perceptions of the bone marrow donation experience. *Bone Marrow Transplant*. 2017 Sep;52(9):1338-1341.
100. Fleischhauer K, Ahn KW, Wang HL, Zito L, Crivello P, Müller C, Verneris M, **Shaw BE**, Pidala J, Oudshorn M, Lee SJ, Spellman SR. Directionality of non-permissive HLA-DPB1 T-cell epitope group mismatches does not improve clinical risk stratification in 8/8 matched unrelated donor hematopoietic cell transplantation. *Bone Marrow Transplant*. 2017 Sep;52(9):1280-1287.
101. Vrooman LM, Millard HR, Brazauskas R, Majhail NS, Battiwalla M, Flowers ME, Savani BN, Akpek G, Aljurf M, Bajwa R, Baker KS, Beitinjaneh A, Bitan M, Buchbinder D, Chow E, Dandoy C, Dietz AC, Diller L, Gale RP, Hashmi SK, Hayashi RJ, Hematti P, Kamble RT, Kasow KA, Kletzel M, Lazarus HM, Malone AK, Marks DI, O'Brien TA, Olsson RF, Ringden O, Seo S, Steinberg A, C Yu L, Warwick A, **Shaw B**, Duncan C. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less Than Three Years of Age. *Biol Blood Marrow Transplant*. 2017 Aug;23(8):1327-1334.
102. Gabriel M, **Shaw B**, Brazauskas R, Chen M, Margolis DA, Sengelov H, Dahlberg A, Ahmed IA, Delgado D, Lazarus HM, Gibson B, Myers KC, Kamble RT, Abdel-Mageed A, Li CK, Flowers MED, Battiwalla M, Savani BN, Majhail N, Shaw P. Risk Factors for Subsequent Central Nervous System (CNS) Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant (HCT): a Study From the Center for International Blood and Marrow Transplant Research (CIBMTR). *Biol Blood Marrow Transplant*. 2017 Aug;23(8):1320-1326.
103. Hamblin A, Greenfield DM, Gilleece M, Salooja N, Kenyon M, Morris E, Glover N, Miller P, Braund H, Peniket A, **Shaw BE**, Snowden JA. Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes. *Bone Marrow Transplant*. 2017 Jun;52(6):889-894.
104. Berro M, Palau Nagore MV, Rivas MM, Longo P, Foncuberta C, Vitriú A, Remaggi G, Martínez Rolon J, Jaimovich G, Requejo A, Feldman L, Padros K, Rodríguez MB, **Shaw BE**, Larripa I, Belli CB, Kusminsky GD. Transforming growth factor- $\beta$ 1 functional polymorphisms in myeloablative sibling hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2017 May;52(5):739-744.
105. **Shaw BE**, Mayor NP, Szydlo RM, Bultitude WP, Anthias C, Kirkland K, Perry J, Clark A, Mackinnon S, Marks DI, Pagliuca A, Potter MN, Russell NH, Thomson K, Madrigal JA, Marsh SG. Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants. *Bone Marrow Transplant*. 2017 May;52(5):717-725.
106. Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, **Shaw BE**, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2017 Mar;23(3):405-411.
107. Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, **Shaw BE**, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, Litzow MR, Pulsipher MA. HRQoL among Older Related HSC



- Donors (>60 Yrs.) is Equivalent to That of Younger Related Donors (18-60 Yrs.): an RDSafe Study. *Biol Blood Marrow Transplant*. 2017 Jan;23(1):165-171.
108. Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, **Shaw BE**, Rizzo JD, Drobyski W, Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. *Bone Marrow Transplant*. 2016 Dec;51(12):1602-1604.
  109. Anthias C, Peniket A, Kirkland K, Madrigal JA, **Shaw BE**. Variations in practice in UK transplant centers: results of a related donor care survey. *Bone Marrow Transplant*. 2016 Dec;51(12):1612-1614
  110. **Shaw BE**, Hahn T, Martin PJ, Mitchell S, Petersdorf EW, Armstrong GT, Shelburne N, Storer B, Bhatia S. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Research Methodology and Study Design. *Biol Blood Marrow Transplant*. 2017 Jan;23(1):10-23.
  111. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Papham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers ME, Savani BN, **Shaw BE**. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1493-1503.
  112. Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller EK, Maziarz RT, Wu J, **Shaw BE**, Confer D, Horowitz MM, Anasetti C. Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. *JAMA Oncol*. 2016 Dec 1;2(12):1583-1589
  113. Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, **Shaw BE**, van Walraven SM, Wiener L, Packman W, Varni JW, Pulsipher MA. Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors. *J Pediatr*. 2016 Nov;178:164-170.e1.
  114. DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Papham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers ME, Savani BN, **Shaw BE**; CIBMTR Late Effects and Quality of Life Working Committee; EBMT Complications and Quality of Life Working Party. Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1493-503.
  115. **Shaw BE**, Lee SJ, Horowitz MM, Wood WA, Rizzo JD, Flynn KE. Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN. *Bone Marrow Transplant*. 2016 Sep;51(9):1173-9.
  116. Szer J, Elmoazzen H, Fechter M, Hwang W, Korhonen M, Miller J, Mengling T, **Shaw B**, Stein J. Safety of Living Donation of Hematopoietic Stem Cells. *Transplantation*. 2016 Jun;100(6):1329-31.

117. Li Z, Rubinstein SM, Thota R, Savani M, Brissot E, **Shaw BE**, Majhail NS, Mohty M, Savani BN. Immune-mediated complications after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2016 Aug;22(8):1368-75.
118. Dignan FL, Clark A, Aitken C, Gilleece M, Jayakar V, Krishnamurthy P, Pagliuca A, Potter MN, **Shaw B**, Skinner R, Turner A, Wynn RF, Coyle P; Haemato-oncology Task Force of the British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation and the UK Clinical Virology Network. BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. *Br J Haematol*. 2016 Feb;172(3):478-81.
119. Sorensen BS, Szer J, **Shaw B**, Korhonen M, Mengling T, Fechter M, Elmoazzen H, Lindberg B, Chapman J, Nørgaard JM, Foeken L, Hwang WY, Nielsen B. Inadvertent completely HLA-mismatched allogeneic unrelated bone marrow transplant: lessons learned. *Bone Marrow Transplant*. 2016 Jul;51(7):1016-8.
120. Anthias C, Billen A, Arkwright R, Szydlo RM, Madrigal JA, **Shaw BE**. Harvests from bone marrow donors who weigh less than their recipients are associated with a significantly increased probability of a suboptimal harvest yield. *Transfusion*. 2016 May;56(5):1052-7.
121. Snowden JA, Danby R, Ruggeri A, Marks DI, Hough RE, Pagliuca A, Potter M, Russell N, Craddock C, Clark A, Miller P, Cook G, Gluckman E, **Shaw BE**, Rocha V. Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service: a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord. *Br J Haematol*. 2016 Feb;172(3):478-81.
122. Arrieta-Bolaños E, Mayor NP, Marsh SG, Madrigal JA, Apperley JF, Kirkland K, Mackinnon S, Marks DI, McQuaker G, Perry J, Potter MN, Russell NH, Thomson K, **Shaw BE**. Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors. *Haematologica*. 2016 Mar;101(3):382-90.
123. Anthias C, **Shaw BE**, Kiefer DM, Liesveld JL, Yared J, Kamble RT, D'Souza A, Hematti P, Seftel MD, Norkin M, DeFilipp ZM, Kasow KA, Abidi MH, Savani BN, Shah NN, Anderlini P, Diaz MA, Malone AK, Halter JP, Lazarus HM, Logan BR, Switzer GE, Pulsipher MA, Confer DL, O'Donnell PV. Significant improvements in the practice patterns of adult related donor care in US transplant centers. *Biol Blood Marrow Transplant*. 2016 Mar;22(3):520-7.
124. Anthias C, O'Donnell PV, Kiefer DM, Yared J, Norkin M, Anderlini P, Savani BN, Diaz MA, Bitan M, Halter JP, Logan BR, Switzer GE, Pulsipher MA, Confer DL, **Shaw BE**. Biol. EBMT transplant centers with FACT-JACIE accreditation have significantly better compliance with related donor care standards. *Biol Blood Marrow Transplant*. 2016 Mar;22(3):514-9.
125. Hough R, Danby R, Russell N, Marks D, Veys P, **Shaw B**, Wynn R, Vora A, Mackinnon S, Peggs KS, Crawley C, Craddock C, Pagliuca A, Cook G, Snowden JA, Clark A, Marsh J, Querol S, Parkes G, Braund H, Rocha V. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. *Br J Haematol*. 2016 Feb;172(3):360-70.
126. Lee JB, Billen A, Lown RN, Potter MN, Craddock CF, de Lavallade H, **Shaw BE**, Sharpe CC. Exacerbation of IgA nephropathy following G-CSF administration for PBSC collection: suggestions for better donor screening. *Bone Marrow Transplant*. 2016 Feb;51(2):286-7.

127. Li Z, Mewawalla P, Stratton P, Yong AS, **Shaw BE**, Hashmi S, Jagasia M, Mohty M, Majhail NS, Savani BN, Rovó A. Sexual health in hematopoietic stem cell transplant recipients. *Cancer*. 2015 Dec 1;121(23):4124-31.
128. Ehrhardt MJ, Brazauskas R, He W, Rizzo JD, **Shaw BE**. Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2016 Jan;51(1):83-8.
129. Bitan M, van Walraven SM, Worel N, Ball LM, Styczynski J, Torrabadella M, Witt V, **Shaw BE**, Seber A, Yabe H, Greinix HT, Peters C, Gluckman E, Rocha V, Halter J, Pulsipher MA. Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a working group of the WBMT Association. *Biol Blood Marrow Transplant*. 2016 Jan;22(1):96-103.
130. Booth GS, Gehrie EA, Jagasia MH, **Shaw BE**, Savani BN. When Can You Discard Stem Cells? *Biol Blood Marrow Transplant*. 2015 Nov;21(11):2033.
131. **Shaw BE**, Logan BR, Kiefer DM, Chitphakdithai P, Pedersen TL, Abdel-Azim H, Abidi MH, Akpek G, Diaz MA, Artz AS, Dandoy C, Gajewski JL, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Majhail NS, O'Donnell PV, Olsson RF, Savani BN, Schears RM, Stroncek DF, Switzer GE, Williams EP, Wingard JR, Wirk BM, Confer DL, Pulsipher MA. An Analysis of the Effect of Race, Socioeconomic Status and Center Size on Unrelated NMDP Donor Outcomes: Donor Toxicities are More Common at Low Volume Bone Marrow Collection Centers. *Biol Blood Marrow Transplant*. 2015 Oct;21(10):1830-8.
132. Srisankarajah P, Webb K, Chisholm D, Raobaikady R, Davis K, Pepper N, Ethell ME, Potter MN, **Shaw BE**. Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients. *Thromb J*. 2015 Jun 25;13:21.
133. Inamoto Y, Shah NN, Savani BN, **Shaw BE**, Abraham AA, Ahmed IA, Akpek G, Atsuta Y, Baker KS, Basak GW, Bitan M, DeFilipp Z, Gregory TK, Greinix HT, Hamadani M, Hamilton BK, Hayashi RJ, Jacobsohn DA, Kamble RT, Kasow KA, Khera N, Lazarus HM, Malone AK, Lupo-Stanghellini MT, Margossian SP, Muffly LS, Norkin M, Ramanathan M, Salooja N, Schoemans H, Wingard JR, Wirk B, Wood WA, Yong A, Duncan CN, Flowers ME, Majhail NS. Secondary solid cancer screening following hematopoietic cell transplantation. *Bone Marrow Transplant*. 2015 Aug;50(8):1013-23.
134. Arrieta-Bolaños E, Madrigal JA, **Shaw BE**. Novel alleles of the transforming growth factor  $\beta$ -1 regulatory region and exon 1. *Bone Marrow Transplant*. 2015 May;50(5):637-41.
135. Anthias C, van Walraven SM, Sørensen BS, de Faveri GN, Fechter M, Cornish J, Bacigalupo A, Müller C, Boo M, **Shaw BE**. Related hematopoietic cell donor care: is there a role for unrelated donor registries? *Bone Marrow Transplant*. 2015 May;50(5):637-41.
136. **Shaw BE**, Confer DL, Hwang W, Pulsipher MA. A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. *Bone Marrow Transplant*. 2015 Mar;50(3):334-40.
137. Billen A, Madrigal JA, Strydom A, Szydlo RM, Switzer GE, **Shaw BE**. Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors. *Biol Blood Marrow Transplant*. 2015 Feb;21(2):350-6
138. Anthias C, Ethell ME, Potter MN, Madrigal A, **Shaw BE**. The impact of improved JACIE standards on the care of related BM and PBSC donors. *Bone Marrow Transplant*. 2015 Feb;50(2):244-7.

139. **Shaw BE**, Lee F, Krishnamurthy S, Byrne JL, Seedhouse C, Mayor NP, Maldonado-Torres H, Saudemont A, Marsh SG, Madrigal JA, Russell NH. Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation. *Bone Marrow Transplant*. 2015 Feb;50(2):237-43.
140. Arrieta-Bolaños E, McWhinnie AJ, Madrigal-Sánchez JJ, Calvo L, Salazar-Sánchez L, Alejandro Madrigal J, Marsh SG, **Shaw BE**. A novel HLA-A allele, A\*74:23, identified in an individual from Costa Rica. *Tissue Antigens*. 2014 Dec;84(6):583-4.
141. Hsu JW, Wingard JR, Logan BR, Chitphakdithai P, Akpek G, Anderlini P, Artz AS, Bredeson C, Goldstein S, Hale G, Hematti P, Joshi S, Kamble RT, Lazarus HM, O'Donnell PV, Pulsipher MA, Savani B, Schears RM, **Shaw BE**, Confer DL. Race and ethnicity influences collection of G-CSF mobilized peripheral blood progenitor cells from unrelated donors, a CIBMTR analysis. *Biol Blood Marrow Transplant*. 2015 Jan;21(1):165-71
142. Scarisbrick JJ, Dignan FL, Tulpule S, Gupta ED, Kolade S, **Shaw B**, Evison F, Shah G, Tholouli E, Mufti G, Pagliuca A, Malladi R, Raj K. A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent. *Bone Marrow Transplant*. 2015 Jan;50(1):62-7.
143. Arrieta-Bolaños E, Alejandro Madrigal J, Marsh SG, **Shaw BE**, Salazar-Sánchez L. The frequency of HLA-B\*57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica. *Hum Immunol*. 2014 Oct 5;75(11):1092-1096.
144. Nikolousis E, Nagra S, Pearce R, Perry J, Kirkland K, Byrne J, Dignan F, Tholouli E, Gilleece M, Russell N, Littlewood T, Cook M, Peniket A, **Shaw BE**, Cook G, Craddock C. Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: A British Society of Blood and Marrow Transplantation study. *Bone Marrow Transplant*. 2015 Jan;50(1):82-6.
145. Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Viña M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW, Prasad V, Robinson J, Saber W, Schultz KR, **Shaw B**, Storek J, Wood WA, Woolfrey AE, Anasetti C. Non-permissive -DPB1 mismatch among otherwise HLA-matched donor-recipient pairs results in increased overall mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation for hematologic malignancies. *Blood*. 2014 Oct 16;124(16):2596-606.
146. Lee F, Luevano M, Veys P, Yong K, Madrigal A, **Shaw BE**, Saudemont A. The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface. *PLoS One*. 2014 Jul 22;9(7):e103254.
147. Fleischhauer K, Fernandez-Viña MA, Wang T, Haagenson M, Battiwalla M, Baxter-Lowe LA, Ciceri F, Dehn J, Gajewski J, Hale GA, Heemskerk MB, Marino SR, McCarthy PL, Miklos D, Oudshoorn M, Pollack MS, Reddy V, Senitzer D, **Shaw BE**, Waller EK, Lee SJ, Spellman SR. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. *Bone Marrow Transplant*. 2014 Sep;49(9):1176-83
148. Feliu J, Clay J, Raj K, Barber L, Devlia V, **Shaw B**, Pagliuca A, Mufti G. Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies. *Br J Haematol*. 2014 Nov;167(3):426-8.
149. Das-Gupta E, Dignan F, **Shaw B**, Raj K, Malladi R, Gennery A, Bonney D, Taylor P, Scarisbrick J. Extracorporeal photopheresis for treatment of adults and children with

- acute GVHD: UK consensus statement and review of published literature. *Bone Marrow Transplant*. 2014 Oct;49(10):1251-8.
150. Billen A, Madrigal JA, Szydlo RM, **Shaw BE**. Female donors and donors who are lighter than their recipient are less likely to meet the CD34+ cell dose requested for peripheral blood stem cell transplantation. *Transfusion*. 2014 Nov;54(11):2953-60.
  151. Pulsipher MA, Chitphakdithai P, Logan BR, Navarro WH, Levine JE, Miller JP, **Shaw BE**, O'Donnell PV, Majhail NS, Confer DL. Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. *Blood*. 2014 Jun 5;123(23):3655-63.
  152. Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, Beksac M, Field S, Yang H, **Shaw BE**. Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee. *Bone Marrow Transplant*. 2014 Jul;49(7):880-6.
  153. Dignan FL, Aguilar S, Scarisbrick JJ, **Shaw BE**, Potter MN, Cavenagh J, Apperley JF, Fielding AK, Pagliuca A, Raj K, Marks DI, Peniket A, Crawley C, Koh MB, Child FJ. Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. *Bone Marrow Transplant*. 2014 May;49(5):704-8.
  154. Anthias C, Dignan FL, Morilla R, Morilla A, Ethell ME, Potter MN, **Shaw BE**. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. *Bone Marrow Transplant*. 2014 May;49(5):679-83.
  155. Billen A, Madrigal JA, **Shaw BE**. A review of the haematopoietic stem cell donation experience: is there room for improvement? *Bone Marrow Transplant*. 2014 Jun;49(6):729-36.
  156. Lown RN, Marsh SG, Switzer GE, Latham KA, Madrigal JA, **Shaw BE**. Ethnicity, length of time on the register and sex predict donor availability at the confirmatory typing stage. *Bone Marrow Transplant*. 2014 Apr;49(4):525-31.
  157. Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, **Shaw BE**, Byrne JL, Brookes C, Craddock CF, Chaganti S. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. *Bone Marrow Transplant*. 2014 Feb;49(2):280-6.
  158. **Shaw BE**, Chapman J, Fechter M, Foeken L, Greinix H, Hwang W, Phillips-Johnson L, Korhonen M, Lindberg B, Navarro WH, Szer J. Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation. *Bone Marrow Transplant*. 2013 Nov;48(12):1506-9.
  159. Lown RN, Tulpule S, Russell NH, Craddock CF, Roest R, Madrigal JA, **Shaw BE**. Subsequent donation requests among 2472 unrelated hematopoietic progenitor cell donors are associated with bone marrow harvest. *Haematologica*. 2013 Dec;98(12):1956-63.
  160. **Shaw BE**, Robinson J, Fleischhauer K, Madrigal JA, Marsh SG. Translating the HLA-DPB1 T-cell epitope-matching algorithm into clinical practice. *Bone Marrow Transplant*. 2013 Nov;48(12):1510-2.
  161. Medd PG, Peniket AJ, Littlewood TJ, Pearce R, Perry J, Kirkland KE, **Shaw BE**, Potter MN, Craddock CF, Milligan DW, Fielding AK, Marks DI, Cook G. Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study. *Bone Marrow Transplant*. 2013 Jul;48(7):982-7.

162. Dignan FL, Potter MN, Ethell ME, Taylor M, Lewis L, Brennan J, McNamara L, Evans SO, Riley U, Davies FE, Dearden CE, Morgan GJ, **Shaw BE**. High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD. *Clin Transplant*. 2013 Jan-Feb;27(1):E56-63.
163. Dignan FL, Manwani R, Potter MN, Ethell ME, Leonard H, Brennan J, Baker J, **Shaw BE**. A dedicated GvHD clinic may improve the quality of life for allogeneic stem cell transplant survivors. *Clin Transplant*. 2013 Jan-Feb;27(1):E1-2.
164. Arrieta-Bolaños E, Madrigal JA, **Shaw BE**. Human leukocyte antigen profiles of latin american populations: differential admixture and its potential impact on hematopoietic stem cell transplantation. *Bone Marrow Res*. 2012;2012:136087.
165. **Shaw BE**. Allogeneic transplantation: When is a mismatch better than a match? *Biol Blood Marrow Transplant*. 2013 Jan;19(1):1-2.
166. Mayor NP, **Shaw BE**, Madrigal JA, Marsh SG. NOD2 Polymorphisms and Their Impact on Haematopoietic Stem Cell Transplant Outcome. *Bone Marrow Res*. 2012;2012:180391.
167. Pulsipher MA, Chitphakdithai P, Logan BR, **Shaw BE**, Wingard JR, Lazarus HM, Waller EK, Seftel M, Stroncek DF, Lopez AM, Maharaj D, Hematti P, O'Donnell PV, Loren AW, Leitman SF, Anderlini P, Goldstein SC, Levine JE, Navarro WH, Miller JP, Confer DL. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the NMDP. *Blood*. 2013 Jan 3;121(1):197-206.
168. Lown RN, **Shaw BE**. 'First do no harm': where do we stand on unrelated hematopoietic cell donor safety? *Expert Rev Hematol*. 2012 Jun;5(3):249-52.
169. Halter JP, van Walraven SM, Worel N, Bengtsson M, Häggglund H, Nicoloso de Faveri G, **Shaw BE**, Schmidt AH, Fechter M, Madrigal A, Szer J, Aljurf MD, Weisdorf D, Horowitz MM, Greinix H, Niederwieser D, Gratwohl A, Kodera Y, Confer D. Allogeneic hematopoietic stem cell donation: standardized assessment of donor outcome data-A WBMT consensus document. *Bone Marrow Transplant*. 2013 Feb;48(2):220-5.
170. Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G, Mahendra P, Taylor PC, Shah P, Lightman S, Fortune F, Kibbler C, Andreyev J, Albanese A, Hadzic N, Potter MN, **Shaw BE**; on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation. Organ-specific management and supportive care in chronic graft-versus-host disease. *Br J Haematol*. 2012 Jul;158(1):62-78.
171. Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, Hadzic N, **Shaw BE**, Potter MN; on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation. Diagnosis and management of acute graft-versus-host disease. *Br J Haematol*. 2012 Jul;158(1):30-45.
172. Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P, Scarisbrick JJ, Taylor PC, **Shaw BE**, Potter MN; on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation. Diagnosis and management of chronic graft-versus-host disease. *Br J Haematol*. 2012 Jul;158(1):46-61.
173. Lown RN, **Shaw BE**. Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision. *Bone Marrow Transplant*. 2013 Feb;48(2):210-9.
174. **Bronwen E Shaw#**, Katharina Fleischhauer#, (joint first author), Theodore Gooley., Mari Malkki, Peter Bardy, Jean-Denis Bignon, Valérie Dubois, Mary M. Horowitz, J Alejandro Madrigal, Yasuo Morishima, Machteld Oudshoorn, Olle Ringden,

- Stephen Spellman, Andrea Velardi, M.D., Elisabetta Zino, B.Sc., Effie W. Petersdorf. A retrospective study of the impact of T cell epitope matching at HLA-DPB1 in recipients of unrelated donor hematopoietic cell transplantation. *Lancet Oncol.* 2012 Apr;13(4):366-74.
175. Arrieta-Bolaños E, Alejandro Madrigal J, **Shaw BE**. Transforming growth factor- $\beta$ 1 polymorphisms and the outcome of hematopoietic stem cell transplantation. *Int J Immunogenet.* 2012 Jun;39(3):192-202.
  176. **Shaw BE**, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Review. *Haematologica.* 2011 Jul;96(7):942-7.
  177. Anoop P, **Shaw BE**, Riley U, Ethell ME, Taj M, Lancaster DL, Atra A, Saso R, Littlewood S, Mohammed K, Davies F, Treleaven J, Morgan GJ, Potter MN. Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysis. *Hematology.* 2011 Jul;16(4):213-20.
  178. Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF, Fielding AK, Pagliuca A, Mufti G, Raj K, Marks DI, Amrolia P, Peniket A, Medd P, Potter MN, **Shaw BE**, Scarisbrick JJ. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. *Bone Marrow Transplant.* 2012 Jun;47(6):824-30.
  179. **Shaw BE**, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN, Wynn R, Gibson B, Pearce RM, Kirkland K, Lee J, Madrigal JA, Cook G, Byrne JL. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. *Br J Haematol.* 2011 Apr;153(2):244-52.
  180. Confer DL, **Shaw BE**, Pamphilon DH. WMDA guidelines for subsequent donations following initial BM or PBSCs. *Bone Marrow Transplant.* 2011 Nov;46(11):1409-12.
  181. Mohammed K, Dignan F, Ethell ME, Davies FE, Morgan GJ, Riley U, Evans S, Potter MN, **Shaw BE**. An early computed tomography-guided antifungal treatment strategy is safe and efficacious in patients undergoing chemotherapy for high-risk acute leukemia. *Leuk Lymphoma.* 2011 Feb;52(2):339-40
  182. Boo M, van Walraven SM, Chapman J, Lindberg B, Schmidt AH, **Shaw BE**, Switzer GE, Yang E, Egeland T. Remuneration of hematopoietic stem cell donors: principles and perspective of the World Marrow Donor Association. *Blood.* 2011 Jan 6;117(1):21-5. Epub 2010 Oct 4.
  183. King RJ, Confer DL, Greinix HT, Halter J, Horowitz M, Schmidt AH, Costeas P, **Shaw B**, Egeland T. Unrelated hematopoietic stem cell donors as research subjects. *Bone Marrow Transplant.* 2011 Jan;46(1):10-3. Epub 2010 Mar 1.
  184. Kanga U, McWhinnie AJ, Mourya M, **Shaw BE**, Madrigal JA, Mehra NK. A novel HLA-DPB1 allele, DPB1\*125:01, identified by sequence-based typing in an Indian individual. *Tissue Antigens.* 2011 Jan;77(1):85-7.
  185. **Shaw BE**, Arguello R, Garcia-Sepulveda CA, Madrigal JA. The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation. *Br J Haematol.* 2010 Aug;150(3):251-8. Epub 2010 Jun 15. Review.
  186. **Shaw BE**. First do no harm. *Blood.* 2010 Jun 17;115(24):4978-9.
  187. Duarte RF, **Shaw BE**, Marín P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martínez-Chamorro C, Mateos-Mazón JJ, Ramírez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH. Plerixafor plus

- granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. *Bone Marrow Transplant*. 2011 Jan;46(1):52-8. Epub 2010 Mar 22.
188. Hiwarkar P, **Shaw BE**, Tredger JM, Brown NW, Kulkarni S, Saso R, Evans S, Treleaven J, Davies FE, Ethell ME, Morgan GJ, Potter MN. Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin. *Clin Transplant*. 2010 Feb 25. [Epub ahead of print]
  189. **Shaw BE**, Ball L, Beksac M, Bengtsson M, Confer D, Diler S, Fechter M, Greinix H, Koh M, Lee S, Nicoloso-De-Faveri G, Philippe J, Pollichieni S, Pulsipher M, Schmidt A, Yang E, van Walraven AM; Clinical Working Group; Ethics Working Group of the WMDA. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. *Bone Marrow Transplant*. 2010 May;45(5):832-8. Epub 2010 Feb 22.
  190. van Walraven SM, Nicoloso-de Faveri G, Axdorph-Nygell UA, Douglas KW, Jones DA, Lee SJ, Pulsipher M, Ritchie L, Halter J, **Shaw BE**. Family donor care management: principles and recommendations. *Bone Marrow Transplant*. 2010 Aug;45(8):1269-73.
  191. **Shaw BE**, Mayor NP, Russell NH, Apperley JF, Clark RE, Cornish J, Darbyshire P, Ethell ME, Goldman JM, Little AM, Mackinnon S, Marks DI, Pagliuca A, Thomson K, Marsh SG, Madrigal JA. Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. *Leukemia*. 2010 Jan;24(1):58-65. Epub 2009 Nov 19.
  192. Berro M, Mayor NP, Maldonado-Torres H, Cooke L, Kusminsky G, Marsh SG, Madrigal AA, **Shaw BE**. Association of functional polymorphisms of the transforming growth factor B1 gene with survival and graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation. *Haematologica*. 2010 Feb;95(2):276-83.
  193. Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, **Shaw BE**, Cook G, Goldstone AH, Marks DI. Favorable outcomes with alemtuzumab conditioned unrelated donor stem cell transplantation in adults with high risk Philadelphia chromosome negative acute lymphoblastic leukemia in first complete remission. *Haematologica*. 2009 Oct;94(10):1399-406
  194. Querol S, Mufti GJ, Marsh SG, Pagliuca A, Little AM, **Shaw BE**, Jeffery R, Garcia J, Goldman JM, Madrigal JA. Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be? *Haematologica*. 2009 Apr;94(4):536-41.
  195. Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, Potter MN, Ethell ME, **Shaw BE**, Morgan GJ. The impact of extramedullary disease at presentation on the outcome of myeloma. *Leuk Lymphoma*. 2009 Feb;50(2):230-5.
  196. Tulpule S, **Shaw BE**, Makoni P, Little AM, Madrigal JA, Goldman JM. Severe allergic reaction with anaphylaxis to G-CSF (lenograstim) in a healthy donor. *Bone Marrow Transplant*. 2009 Jul;44(2):129-30.
  197. **Shaw BE**, Veys P, Pagliuca A, Addada J, Cook G, Craddock CF, Gennery AR, Goldman J, Mackinnon S, Madrigal JA, Marks DI, Navarrete C, Potter MN, Querol S, Regan F, Russell NH, Hough RE. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. *Bone Marrow Transplant*. 2009 Jul;44(1):7-12.
  198. Dignan FL, Evans SO, Ethell ME, **Shaw BE**, Davies FE, Dearden CE, Treleaven JG, Riley UB, Morgan GJ, Potter MN. An early CT-diagnosis-based treatment strategy



- for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. *Bone Marrow Transplant*. 2009 Jul;44(1):51-6.
199. **Shaw BE**. The clinical implications of HLA mismatches in unrelated donor haematopoietic cell transplantation. *Int J Immunogenet*. 2008 Aug;35(4-5):367-74.
  200. **Shaw BE**, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towilson KE, Apperley JF, Chakraverty R, Craddock CF, Kazmi MA, Littlewood TJ, Milligan DW, Pagliuca A, Thomson KJ, Marks DI, Russell NH. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. *Bone Marrow Transplant*. 2008 Dec;42(12):783-9.
  201. Mayor NP, **Shaw BE**, Madrigal JA, Marsh SG. No impact of NOD2/CARD15 on outcome after SCT: a reply. *Bone Marrow Transplant*. 2008 Dec;42(12):837-8.
  202. Srikanth M, Davies FE, Wu P, Jenner MW, Ethell ME, Potter MN, **Shaw BE**, Saso RM, Dines S, Morgan GJ. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. *Eur J Haematol*. 2008 Dec;81(6):432-6. Epub 2008 Aug 6.
  203. Tholouli E, Liakopoulou E, Greenfield HM, **Shaw BE**, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH, Liu Yin JA. Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. *Br J Haematol*. 2008 May 19. [Epub ahead of print]
  204. Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL, **Shaw BE**, McMillan A, Gonzalez J, Ho A, Mufti GJ, Pagliuca, A. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. *Br J Haematol*. 2008; 141(2): 235-43
  205. **Shaw BE**, Russell NH. Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. *Bone Marrow Transplant*. 2008; 41(5): 495-503
  206. Mayor NP, **Shaw BE**, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, et al. In reply: NOD2/CARD15 Polymorphisms in Allogeneic Stem-Cell Transplantation From Unrelated Donors: T Depletion Matters. *J Clin Oncol* 2008; 26(2): 339
  207. Madrigal A, **Shaw BE**. Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation. *Blood Cells Mol Dis* 2008;40(1):40-3.
  208. Bishton MJ, Lush RJ, Byrne JL, Russell NH, **Shaw BE**, Haynes AP. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. *Br J Haematol* 2007;136(5):752-61.
  209. Das-Gupta EP, Russell NH, **Shaw BE**, Pearce RM, Byrne JL. Long-Term Outcome of Unrelated Donor Transplantation for AML Using Myeloablative Conditioning Incorporating Pretransplant Alemtuzumab. *Biol Blood Marrow Transplant* 2007;13(6):724-33.
  210. Mayor NP, **Shaw BE**, Keshav S, Madrigal JA, Marsh SG. A novel technique for NOD2/CARD15 genotyping using PCR-SSP. *J Immunol Methods* 2007;327(1-2):82-7.
  211. Mayor NP, **Shaw BE**, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, et al. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. *J Clin Oncol* 2007;25(27):4262-9.

212. **Shaw BE**, Gooley T, Madrigal JA, Malkki M, Marsh SG, Petersdorf EW. Clinical importance of HLA-DPB1 in haematopoietic cell transplantation. *Tissue Antigens* 2007;69 Suppl 1:36-41.
213. **Shaw BE**, Byrne JL, Das-Gupta E, Carter GI, Russell NH. The Impact of Chimerism Patterns and Predonor Leukocyte Infusion Lymphopenia on Survival following T Cell-Depleted Reduced Intensity Conditioned Transplants. *Biol Blood Marrow Transplant* 2007;13(5):550-9.
214. **Shaw BE**, Boswell T, Byrne JL, Yates C, Russell NH. Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. *Bone Marrow Transplant* 2007;39(10):623-9.
215. **Shaw BE**. Practical hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2007;40(5):503.
216. **Shaw BE**, Gooley TA, Malkki M, Madrigal JA, Begovich AB, Horowitz MM, et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. *Blood* 2007;110(13):4560-6.
217. Duarte RF, Pamphilon D, Cornish J, **Shaw BE**, Samson D, Craddock C, et al. Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005. *Bone Marrow Transplant* 2006;37(10):901-8.
218. **Shaw BE**, Marsh SG, Mayor NP, Russell NH, Madrigal JA. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. *Blood* 2006;107(3):1220-6.
219. Duarte RF, Delgado J, **Shaw BE**, Wrench DJ, Ethell M, Patch D, et al. Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver. *Biol Blood Marrow Transplant* 2005;11(10):805-13.
220. Kroger N, **Shaw B**, Iacobelli S, Zabelina T, Peggs K, Shimoni A, et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. *Br J Haematol* 2005;129(5):631-43.
221. Mayor NP, Cox ST, McWhinnie AJ, Arguello JR, **Shaw BE**, Little AM, et al. Sequence of a novel HLA-A\*0301 intronic variant (A\*03010103). *Tissue Antigens* 2005;65(1):107-9.
222. **Shaw BE**, Russell NH, Devereux S, Das-Gupta E, Mackinnon S, Madrigal JA, et al. The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. *Haematologica* 2005;90(11):1562-9.
223. **Shaw BE**, Maldonado H, Madrigal JA, Smith C, Petronzelli F, Mayor NP, et al. Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation. *Tissue Antigens* 2004;63(5):401-11.
224. **Shaw BE**, Barber LD, Madrigal JA, Cleaver S, Marsh SG. Scoring for HLA matching? A clinical test of HistoCheck. *Bone Marrow Transplant* 2004;34(4):367-8.
225. Madrigal JA, Garcia CA, Gutierrez M, **Shaw BE**, Arguello R, Little A-M, et al. El complejo mayor de histocompatibilidad y su papel biologica. HLA y su papel en la evolucion clinica de trasplantes y enfermedades autoinmunes. *Hematologia* 2003;6(4):1-8.
226. **Shaw BE**, Potter MN, Mayor NP, Pay AL, Smith C, Goldman JM, et al. The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and

- disease relapse following haematopoietic stem cell transplantation. *Bone Marrow Transplant* 2003;31(11):1001-8.
227. **Shaw BE**, Peggs K, Bird JM, Cavenagh J, Hunter A, Alejandro Madrigal J, et al. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. *Br J Haematol* 2003;123(5):886-895.
228. **Shaw B**, Mehta AB. Pancytopenia responding to treatment of hyperthyroidism: a clinical case and review of the literature. *Clin Lab Haematol* 2002;24(6):385-7.
229. **Shaw BE**, Perry D, Hoffbrand AV. Progressive arterial thrombosis in a patient with non-Hodgkin's lymphoma, a lupus anticoagulant, factor V Leiden mutation and paraprotein, following chemotherapy. *Leuk Lymphoma* 2001;42(1-2):221-3.
230. **Shaw BE**, Madrigal JA, Potter M. Improving the outcome of unrelated donor stem cell transplantation by molecular matching. *Blood Rev* 2001;15(4):167-74.
231. Chopra R, Eaton JD, Grassi A, Potter M, **Shaw B**, Salat C, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. *Br J Haematol* 2000;111(4):1122-9.
232. Paterson PJ, Marshall SR, **Shaw B**, Kendra JR, Ethel M, Kibbler CC, et al. Fatal invasive cerebral *Absidia corymbifera* infection following bone marrow transplantation. *Bone Marrow Transplant* 2000;26(6):701-3.
233. Somers LJ, **Shaw B**, Lyn BE, McMillan AM, Mahendra P. Meningeal myeloma in the absence of systemic disease, and as the initial feature of disease progression. *Clin Lab Haematol* 1998;20(3):189-90.

### **Chapters**

1. **Bronwen E. Shaw**. Patient and Donor Selection and Workup for Hematopoietic Cell Transplantation. In: Hematopoietic Cell Transplantation for Malignant Conditions. Editors: Qaiser Bashir and Mehdi Hamadani. Elsevier, 2019.
2. Bowles KM, Collins A, **Shaw BE**, Thomas W. Haematology and Oncology. In: Medical Masterclass (3rd edition). Bowles KM, Ed. Firth J, ed-in-chief. London: Royal College of Physicians of London; 2018.
3. **Bronwen E. Shaw** and Stephen R. Spellman. HLA typing and implications. In: Clinical Manual of Blood and Bone Marrow Transplantation. Editors: Syed A. Abutalib, Parameswaran Hari. Wiley-Blackwell, June 2017.
4. Stephen R. Spellman and **Bronwen E. Shaw**. Unrelated Donor Selection: Human Leukocyte Antigen Testing and Matching—Permissive and Non-permissive Matches. In: Hematopoietic Cell Transplants Hardback with Online Resource: Concepts, Controversies and Future Directions (1st Edition). Editors: Hillard M. Lazarus, Robert Peter Gale, Armand Keating, Andrea Bacigalupo, Reinhold Munker, Kerry Atkinson, Syed Ali Abutalib. Cambridge University Press, 2017.
5. **Bronwen E. Shaw**, Alejandro Madrigal. Immunogenetics of allogeneic HSCT. In: ESH-EBMT Handbook on HSCT (6th Edition). Editors: Jane Apperley, Enric Carreras, Eliane Gluckman, Tamas Masszi; 2012.
6. **Bronwen E Shaw**. Human leukocyte antigen matching, compatibility testing and donor selection. In Hematopoietic Stem Cell Transplantation in Clinical Practice. Eds. Treleaven J. and Barrett A.J. Pub. Churchill Livingstone, Edinburgh, UK, p. 239-47, 2009.
7. Bower M, Bowles KM, Brock CS, Dark GG, Fife KM, Galvani DW, Olujohungbe ABK, **Shaw BE**. Haematology and Oncology. In: Medical Masterclass (2nd edition). Firth J, ed. London: Royal College of Physicians of London; 2008.
8. **Bronwen Shaw**, Simon O'Connor, Andrew P Haynes. Lymphoproliferative Disorders Including Chronic Lymphocytic Leukaemia. In: ABC of Clinical Haematology (3rd edition). Provan, D, ed. London: Blackwell BMJ Books; 2007.

9. Bower M, Bowles KM, Dark GG, Galvani DW, **Shaw BE**. Haematology and Oncology. In: Medical Masterclass. Firth J, ed. London: Blackwell Science; 2001.

### **Workshop Proceedings**

1. Bronwen E Shaw and Michael D Varney on behalf of participating laboratories. Haemopoietic Stem Cell Component- HLA-DPB1 joint report. In: Immunobiology of the Human MHC. Proceedings of the 13<sup>th</sup> International Histocompatibility Workshop and Conference. Hansen J, Ed. Seattle: IHWG Press. 2007
2. Bronwen E Shaw, Steven G E Marsh, J Alejandro Madrigal. Role of HLA matching in unrelated donor transplant—An update of the Anthony Nolan data. In: Immunobiology of the Human MHC. Proceedings of the 13<sup>th</sup> International Histocompatibility Workshop and Conference. Hansen J, Ed. Seattle: IHWG Press. 2007
3. B. E. Shaw, M. N. Potter, H. Grant Prentice, N. Mayor, A. L. Pay, S. G. E. Marsh and J. A. Madrigal. Graft versus host disease in matched T cell depleted unrelated donor haematopoietic stem cell transplants. In: Immunobiology of the Human MHC. Proceedings of the 13<sup>th</sup> International Histocompatibility Workshop and Conference. Hansen J, Ed. Seattle: IHWG Press. 2007
4. B.E. Shaw, M.N. Potter, H. Grant Prentice, N. Mayor, A.L. Pay, P. Travers, S. G. E. Marsh and J.A. Madrigal. Disease relapse following volunteer donor haematopoietic stem cell transplantation. In: Immunobiology of the Human MHC. Proceedings of the 13<sup>th</sup> International Histocompatibility Workshop and Conference. Hansen J, Ed. Seattle: IHWG Press. 2007

### **Internet**

Regular contributions to the Medical Masterclass website of MCQs.  
Haematology MCQs prepared for MRCP I in the form of a CR-ROM for Blackwell Science Limited. Now included in Medical Masterclass website/paper modules.

## **FIRST AUTHOR ONLY ABSTRACTS ACCEPTED FOR PRESENTATION (SINCE 2015)**

- |          |  |
|----------|--|
| Mar 2016 | <b>Oral Presentations at EBMT, Valencia</b><br>Centralized patient reported quality of life collection in HCT patients is feasible, and higher pre-HCT scores significantly predict better overall survival post-transplant<br>Bronwen E Shaw, Ruta Brazauskas, Heather R Millard, Rachel Fonstad, Kathryn Flynn, Amy Abernethy, Jenny Vogel, Charney Petroske, Deborah Mattila, Rebecca Drexler, Stephanie J Lee, Mary M Horowitz and J Douglas Rizzo |
| Oct 2016 | <b>Oral Presentations at ISOQOL, Copenhagen</b><br>Patient-reported outcome scores significantly predict overall survival for patients undergoing allogeneic hematopoietic cell transplants<br>Bronwen E Shaw, Ruta Brazauskas, Heather R Millard, Rachel Fonstad, Kathryn E Flynn, Amy Abernethy, Jenny Vogel, Charney Petroske, Deborah Mattila, Rebecca Drexler, Stephanie J Lee, Mary M Horowitz and J Douglas Rizzo                               |
| Feb 2017 | <b>Oral Presentations at BMT Tandem, Orlando</b><br>PROMIS and SF36 Patient Reported Outcome Scores Are Strongly Correlated in Transplant Survivors  |

- Oct 2017 Bronwen E. Shaw, Lynn Onstad, K. Scott Baker, Eric J Chow, Mary E. D. Flowers, Heather Jim, Karen L. Syrjala and Stephanie J. Lee  
**Oral Presentations at PHO, Philadelphia**  
PROMIS in Hematopoietic cell transplantation (HCT)
- Dec 2017 Bronwen E Shaw, Roxanne E Jensen, Lynn Onstad, Karen L. Syrjala, Eric J Chow, Mary E. Flowers, Heather Jim, K Scott Baker, Sarah Buckley, Diane L Fairclough, Mary M Horowitz, Stephanie J. Lee  
**Oral Presentations at ASH, Atlanta**  
Analysis of 10,462 8/8 HLA- matched unrelated donor transplants could not identify a donor selection score, as younger age is the only significant donor characteristic associated with survival  
Bronwen E. Shaw; Brent R. Logan; Stephen R. Spellman; Steven GE Marsh; James Robinson; Joseph Pidala; Carolyn Hurley; Juliet Barker; Martin Maiers; Jason Dehn; Hailin Wang; Mike Haagenson; David Porter; Effie W. Petersdorf; Ann Woolfrey; Mary M. Horowitz; Michael Verneris; Katharine C. Hsu; Katharina Fleischhauer; Stephanie J. Lee
- Feb 2020 **Oral Presentations at TCT, Orlando**  
Feasibility of centralized electronic Patient-Reported Outcome (ePRO) collection by an outcome registry, a CIBMTR study of patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) myelodysplasia protocol  
Bronwen Shaw, Linda J Burns, Deborah Mattila, Alisha Mussetter, Min Chen, Sumithira Vasu, Joseph Pidala, Lori Muffly, Joseph Uberti, Roni Tamari, Erin Leckrone, Judy Myers, Ruta Bruzauskas, Lih-Wen Mau, J Douglas Rizzo, Wael Saber, Mary Horowitz, Stephanie Lee, Kathryn Flynn
- Oct 2020 **Oral presentation at PHO, virtual platform**  
Incorporating PROs in the CIBMTR hematopoietic cell transplant outcomes registry to enhance QOL research  
Bronwen E Shaw, Deborah Mattila, Linda J Burns, Ruta Brazauskas, Erin Leckrone, Rachel Cusatis, Kathryn E Flynn
- Oct 2020 **Oral presentation at ISOQOL, virtual platform**  
Allogeneic hematopoietic cell transplantation (HCT) for patients over 65 years old is not associated with worse symptoms/function than younger patients, a Center for International Blood and Marrow Transplant Research (CIBMTR) study of patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) myelodysplasia protocol  
Bronwen Shaw, Linda J Burns, Deborah Mattila, Alisha Mussetter, Min Chen, Sumithira Vasu, Joseph Pidala, Lori Muffly, Joseph Uberti, Roni Tamari, Erin Leckrone, Judy Myers, Ruta Bruzauskas, Lih-Wen Mau, J Douglas Rizzo, Wael Saber, Mary Horowitz, Stephanie Lee, Kathryn Flynn